This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kloner, R. A. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Kloner, R. A. Articles by Braunwald, E. Related Collections AHA Statements and Guidelines

(Circulation. 1998;97:1848-1867.)
© 1998 American Heart Association, Inc.

Special Reports

Medical and Cellular Implications of Stunning, Hibernation, and Preconditioning

An NHLBI Workshop

Robert A. Kloner, MD, PhD; Roberto Bolli, MD; Eduardo Marban, MD, PhD; Leslie Reinlib, PhD; ; Eugene Braunwald, MD

From the Heart Institute, Good Samaritan Hospital, and University of Southern California, Los Angeles (R.A.K.); University of Louisville (R.B.), Louisville, Ky; Johns Hopkins University (E.M.), Baltimore, Md; Harvard Medical School, Brigham and Women's Hospital (E.B.), Boston, Mass; and the National Heart, Lung, and Blood Institute (L.R.), Bethesda, Md.

Key Words: stunning, myocardial • hibernation • preconditioning • ischemia • infarction

	Introduction

Top Introduction Myocardial Stunning Hibernating Myocardium Preconditioning Summary Appendix References

 
On July 2–3, 1996, the National Heart, Lung, and Blood Institute sponsored a workshop in Columbia, Md, entitled "The Medical and Cellular Implications of Myocardial Stunning, Hibernation, and Preconditioning." The goals of this workshop were to identify and discuss the areas of agreement and controversy regarding these important phenomena and in particular to identify areas of future research for each. One aspect of these goals included determination of the mechanisms of these phenomena. Stunning is a form of prolonged contractile dysfunction that occurs after relief of a discrete episode or episodes of ischemia; hibernation is a form of prolonged contractile dysfunction associated with ongoing low blood flow, although controversy exists as to whether absolute blood flow or coronary reserve is reduced and whether it may represent repetitive bouts of stunning. Preconditioning is a cardioprotective mechanism in which the heart is exposed to a controlled, short period of sublethal ischemia that attenuates cellular damage from a subsequent prolonged lethal episode of ischemia. Research efforts have not yet provided a clear understanding of all aspects of these conditions. The workshop presented the current state of both basic science knowledge and clinical knowledge of these disorders, promoted discussions between basic and clinical scientists, and identified likely mechanisms and new directions for research.

The meeting was chaired by Eugene Braunwald and cochaired by Roberto Bolli, Eduardo Marban, and Robert A. Kloner and was coordinated by Leslie Reinlib. Twenty participants represented a broad spectrum of expertise: basic and clinical scientists, pathologists, and surgeons. (A list of conference participants is provided in the Appendix.)

The purpose of this article is to review some of the points made at the workshop in regard to areas of general agreement and controversy and, most importantly, to summarize the areas that need further research. The following discussions briefly review the concepts of stunning, hibernating, and preconditioning discussed at the workshop and some additional material that has become available since the workshop. Following each brief discussion are suggestions made by the panel for future research directions.

	Myocardial Stunning

Top Introduction Myocardial Stunning Hibernating Myocardium Preconditioning Summary Appendix References

 
The Protean Nature of Myocardial Stunning
Myocardial stunning is a general term that describes the mechanical dysfunction that persists after reperfusion despite the absence of irreversible damage and despite return of normal or near-normal perfusion.^{1 2} This phenomenon was first described by Heyndrickx et al³ in 1975 in conscious dogs undergoing brief coronary occlusions. One of the major problems in formulating a unifying pathophysiological and pathogenetic paradigm for myocardial stunning is that this phenomenon occurs in a wide variety of settings that differ from one another in several major respects.² Indeed, myocardial stunning might be regarded not as a single entity but instead as a phenomenon. At the experimental level, the available observations can be grouped into six categories² : (1) stunning after a single, completely reversible episode of regional ischemia in vivo (eg, a coronary occlusion <20 minutes in the dog), as originally described by Heyndrickx et al^{3 4 5 6} ; (2) stunning after multiple, completely reversible episodes of regional ischemia in vivo (eg, repeated 5- or 10-minute coronary occlusions in the dog)^{7 8 9 10 11} ; (3) stunning after a partly reversible (no necrosis) plus partly irreversible (some areas of necrosis) episode of regional ischemia in vivo (eg, a coronary occlusion >20 minutes but <3 hours in the dog)^{12 13} (this category may be relevant to patients who receive thrombolysis or angioplasty for acute myocardial infarction and then demonstrate delayed recovery of function of the salvaged tissue); (4) stunning after global ischemia in vitro (isolated heart preparations)^{14 15 16 17 18 19} ; (5) stunning after global ischemia in vivo (cardioplegic arrest)^{20 21 22 23} ; and (6) stunning after exercise-induced ischemia (high-flow ischemia).^{24 25 26} Because of the heterogeneity of these settings, it is possible that findings developed in one setting may not be applicable to another.² Thus, an important, unresolved issue is whether all forms of stunning share a common pathogenesis.

Pathogenesis of Myocardial Stunning
Myocardial stunning is probably a multifactorial process that involves complex sequences of cellular perturbations and the interaction of multiple pathogenetic mechanisms.² The most plausible hypotheses regarding the pathogenesis of myocardial stunning are the oxyradical hypothesis and the calcium hypothesis. The oxyradical hypothesis postulates that stunning is caused by oxidant stress secondary to the generation of ROS.^{2 27} In a very broad sense, the calcium hypothesis postulates that stunning is the result of a disturbance of cellular calcium homeostasis.^{2 28 29} As pointed out previously,² these theories are not mutually exclusive and probably represent different facets of the same pathophysiological process. A unifying hypothesis for the pathogenesis of myocardial stunning is proposed in Fig 1A.

View larger version (58K): [in this window] [in a new window]   Figure 1. A, Illustration of the proposed pathogenesis of postischemic myocardial dysfunction. This proposal integrates and reconciles different mechanisms into a unifying pathogenetic hypothesis. Transient reversible ischemia followed by reperfusion could result in increased production of superoxide radicals ( ·O2-) through several mechanisms, including the following: (1) increased activity of xanthine oxides; (2) activation of neutrophils; (3) activation of the arachidonate cascade; (4) accumulation of reducing equivalents during oxygen deprivation; (5) derangements of the mitochondrial electron transport system resulting in increased univalent reduction of oxygen; and (6) autoxidation of catecholamines and other substances. Superoxide dismutase (SOD) dismutates ·O2- to hydrogen peroxide (H2O2); in the presence of catalytic iron, ·O2- and H2O2 interact in a Haber-Weiss reaction to generate the hydroxyl radical (·OH). H2O2 can also generate ·OH in the absence of ·O2- through a Fenton reaction provided that other substances (such as ascorbate) reduce Fe (III) to Fe (II). ·O2- and ·OH attack proteins and polyunsaturated fatty acids, causing enzyme inactivation and lipid peroxidation, respectively. In the setting of reversible ischemia, the intensity of this damage is not sufficient to cause cell death but is sufficient to produce dysfunction of key cellular organelles. Postulated targets of free radical damage include the following: (1) the sarcolemma, with consequent loss of selective permeability, impairment of calcium-stimulated ATPase activity and calcium transport out of the cell, and impairment of the Na+-K+-ATPase activity; the net result of these perturbations would be increased transsarcolemmal calcium influx and cellular calcium overload; (2) the sarcoplasmic reticulum, with consequent impairment of calcium-stimulated ATPase activity and calcium transport; this would result in decreased calcium sequestration (which would contribute to increase free cytosolic calcium) and decreased calcium release during systole (which would cause excitation-contraction uncoupling); and (3) other structures, such as the extracellular collagen matrix (with consequent loss of mechanical coupling) or the contractile proteins (with consequent decreased responsiveness to calcium); for example, free radicals could oxidize thiol groups in myofilaments, causing impaired Ca2+ sensitivity. At the same time, reversible ischemia/reperfusion could cause cellular Na+ overload due to (1) inhibition of sarcolemmal Na+-K+-ATPase and (2) acidosis and Na+-H+ exchange. This could further exaggerate calcium overload via increased Na+-Ca2+ exchange. An increase in free cytosolic calcium would activate protein kinases, phospholipases, and other degradative enzymes and further exacerbate the injury to the aforementioned key subcellular structures (sarcolemma, sarcoplasmic reticulum, and contractile proteins). Thus, calcium overload could serve to amplify the damage initiated by oxygen radicals. In addition, calcium overload could in itself impair contractile performance and contribute to mechanical dysfunction. It is also possible that the increase in free cytosolic calcium could increase oxyradical production by promoting the conversion of xanthine dehydrogenase to xanthine oxidase. The ultimate consequence of this complex series of perturbations is a reversible depression of contractility. Reproduced with permission of the American Heart Association from Bolli (Circulation. 1990;82:723–738). B, Possible components of postischemic dysfunction. Myocardial stunning probably arises from the additive effects of a reperfusion-induced pathology (identified, as least in part, by the fraction [dark shading] of the contractile deficit, which can be restored through the use of an antioxidant intervention given transiently at the time of reperfusion) and a second component (light shading), which incorporates the ischemic pathology from which the heart is slowly recovering, together with any additional reperfusion-induced component that is not amenable to the chosen intervention. Reproduced with permission, Hearse DG. Stunning: a radical review. In: Opie LH, ed. Stunning, Hibernation, and Calcium in Myocardial Ischemia and Reperfusion. Boston, Mass: Kluwer Academic Press; 1992:10–55.

Generation of ROS (Oxyradical Hypothesis)
It is now generally accepted that ROS play an important role in the pathogenesis of myocardial stunning in the following experimental settings (as reviewed in Reference 27²⁷ ): (1) after a single, completely reversible episode of regional ischemia in vivo^{30 31 32} ; (2) after multiple, completely reversible episodes of regional ischemia in vivo^{9 33} ; (3) after global ischemia in vitro^{18 19 34 35 36} ; and (4) after global ischemia in vivo.^{20 21 22 23} For example, in the first setting (coronary occlusion <20 minutes), alleviation of stunning by antioxidant therapies has been reproducibly observed by several independent laboratories in a variety of animal models and species.³⁷ Similar protective effects of antioxidants have subsequently been demonstrated in conscious animals.^{33 38 39} At the time of this writing, at least 22 full-length articles have been published that have examined the effect of antioxidants on myocardial stunning after a 15-minute coronary occlusion; all of these articles (except those that used superoxide dismutase alone^{40 41 42} or catalase alone⁴⁰ ) have reported a protective effect of antioxidants against stunning.³⁷ Furthermore, generation of ROS in stunned myocardium has been demonstrated directly by both spin trapping^{9 39 43 44 45 46 47} and aromatic hydroxylation⁴⁸ techniques, and attenuation of ROS generation has repeatedly been shown to result in attenuation of contractile dysfunction.^{9 39 43 45 46} A role of ROS in the genesis of myocardial stunning can now be regarded as a proven hypothesis. Nevertheless, it remains unclear whether ROS play a role in all settings of stunning. There is presently no evidence that they contribute to exercise-induced postischemic dysfunction.⁴⁹ Data regarding the effects of antioxidants on myocardial stunning after a prolonged (>20 but <180 minutes) ischemic insult, causing some subendocardial infarction and adjacent areas of stunning, are conflicting (reviewed in Reference 37³⁷ ); thus, the role of ROS in this setting is uncertain.

The available evidence indicates that most or all of the ROS-mediated injury responsible for stunning occurs in the initial moments of reperfusion. For example, in the setting of a 15-minute coronary occlusion in the dog, antioxidant therapies are equally effective in alleviating myocardial stunning irrespective of whether they are begun before ischemia or just prior to reperfusion; however, antioxidant therapies begun 1 minute after reperfusion are ineffective, indicating that the ROS important in causing myocardial stunning are those produced immediately after reflow.^{43 46} Thus, myocardial stunning can be viewed in part as a form of ROS-mediated "reperfusion injury."^{27 43} This concept may have significant therapeutic implications because it suggests that antioxidant therapies begun after the onset of ischemia could still be effective in preventing postischemic dysfunction; however, a delay in the implementation of such therapies until after reperfusion would result in loss of efficacy.²⁷ It is important to stress, however, that none of the antioxidant therapies used thus far has completely prevented myocardial stunning.²⁷ On the basis of these observations, it seems reasonable to conclude that the injury responsible for myocardial stunning consists of two components: (1) a component that develops during ischemia (ischemic injury) and is not responsive to antioxidant therapy (no matter how vigorous or how early applied) and (2) a component that develops after reperfusion (reperfusion injury) and can be mitigated by early antioxidant therapy (Fig 1B).^{27 50} Judging from the effects of antioxidants, the reperfusion injury component appears to be larger than the ischemic injury component.²⁷

The exact source of ROS production in stunned myocardium remains uncertain (Fig 1A), but two points are clear: (1) neutrophils do not contribute to stunning after reversible ischemia in vivo,^{51 52} and (2) xanthine oxidase is not necessary for ROS to be generated in sufficient quantities to induce stunning, because ROS also participate in the genesis of postischemic dysfunction in xanthine oxidase–deficient species.^{33 42 53} The exact mechanism whereby ROS depress contractile function remains to be determined (Fig 1A). The number of potential molecular targets is vast because ROS can attack nonspecifically virtually all cellular components. ROS have been shown to interfere with a number of ion transport mechanisms in the sarcolemma, including Ca²⁺ ATPase,^{54 55} Na⁺-K⁺ATPase,⁵⁶ and the Na⁺-Ca²⁺ exchanger,⁵⁷ that would result in increased transsarcolemmal Ca²⁺ influx and cellular Ca²⁺ overload. Transient exposure to ROS has also been found to decrease the responsiveness of myofilaments to Ca²⁺⁵⁸ and to impair the function of sarcoplasmic reticulum.⁵⁹ Investigation of the manner in which ROS perturb Ca²⁺ homeostasis and/or Ca²⁺ responsiveness is important not only because it should elucidate the pathogenesis of stunning but also because it may reconcile the oxyradical and Ca²⁺ hypotheses of stunning into one pathogenic mechanism (Fig 1A).

Availability of Activator Ca²⁺
In the setting of global ischemia in vitro, myocardial stunning is not caused by decreased availability of activator Ca²⁺. Measurements of free cytosolic [Ca²⁺] (using gated NMR, aequorin, or fura 2) in this setting have shown the Ca²⁺ transients to be normal or even increased in stunned myocardium.^{15 60 61} Although Ca²⁺ transport has been found to be impaired in sarcoplasmic reticulum isolated from an in vivo model of stunned myocardium,⁶² no data are available regarding Ca²⁺ transients in stunned myocardium in vivo because there is currently no technique that enables measurements of free cytosolic [Ca²⁺] in this situation.

Ca²⁺ Overload
On the other hand, there is considerable evidence that a transient Ca²⁺ overload during the early phase of reperfusion contributes to the pathogenesis of myocardial stunning after global ischemia in vitro^{14 17 28 60} (Fig 1A). Indirect evidence indicates that Ca²⁺ overload also contributes to postischemic dysfunction after regional ischemia in vivo,⁶³ but direct demonstration of this concept is still lacking. The mechanism whereby Ca²⁺ overload causes contractile dysfunction remains unknown.

Decreased Sensitivity of Myofilaments to Ca²⁺
Studies in models of stunning after global ischemia in vitro^{14 15} and in ventricular trabeculae isolated from these models⁶¹ have concluded that the alteration responsible for the contractile dysfunction consists of a decrease both in the maximal Ca²⁺-activated force and the sensitivity of myofilaments to Ca²⁺. A decrease in Ca²⁺ sensitivity of myofilaments has not been observed consistently in all models of global ischemia in vitro, however.⁶⁰ Studies in single myocytes obtained from a porcine model of myocardial stunning caused by reversible ischemia in vivo have demonstrated that the Ca²⁺ sensitivity of tension was markedly decreased with no resolvable change in maximal tension.⁶⁴ Interestingly, this decrease in Ca²⁺ sensitivity occurs after reperfusion, not during ischemia, further supporting the notion that stunned myocardium is a manifestation of reperfusion injury.⁶⁵ This decrease in Ca²⁺ sensitivity of tension appears to be due at least in part to alterations in the cardiac troponin regulatory complex.⁶⁶ The loss of Ca²⁺ sensitivity, however, is not a universal feature of stunned myocardium in this porcine model, because it was observed after a severe ischemic insult but not after milder insults.⁶⁷ Nevertheless, cells from such "mildly" ischemic regions do display abnormally slow cross-bridge cycling, indicative of myofilament injury.⁶⁷

If stunned myocardium is due to a decrease in Ca²⁺ sensitivity, it is clear that this reduced sensitivity can be overcome. A variety of inotropic agents can stimulate the stunned myocardium to contract, and it is clear that stunned myocardium manifests contractile reserve.^{68 69 70} This is good news in the clinical realm because it means that stunned myocardium can be recruited to contract if needed.

Summary
It appears that one of the lesions responsible for myocardial stunning after global ischemia in vitro and regional reversible ischemia in vivo is an alteration of the contractile proteins resulting in decreased responsiveness of the contractile machinery to Ca²⁺ (Fig 1A), so that for any given Ca²⁺ transient, the myocardium generates less force. In this sense, myocardial stunning could be viewed as a disturbance of myofilament function. However, it is not yet clear whether or not myofilament alterations are a general feature of all forms of stunning.

The exact nature of the myofibrillar defect is an important area for future investigation. It has been hypothesized that stunning is the result of the activation of endogenous proteases that attack the myofilaments and that the slow recovery of the stunned myocardium is caused by the slow synthesis of new contractile proteins to repair the damage.^{28 71} In particular, partial proteolysis of troponin I has been demonstrated in globally stunned myocardium.⁶⁶ The impaired responsiveness of contractile filaments may also be caused by oxidation of critical thiol groups, which could be quickly reversed on normalization of the cellular redox state² (Fig 1A).

Repetitive Stunning Versus Hibernation
A major unresolved issue that has important pathophysiological and clinical implications is whether repetitive episodes of myocardial stunning can account for at least some of the clinical manifestations of so-called myocardial hibernation (ie, the syndrome of reversible ventricular dysfunction thought to be secondary to a primary deficit of coronary flow and initially referred to as "chronic stunning").¹ Animal studies have shown that repeated brief bouts of ischemia have a cumulative effect on contractility, such that the duration and severity of myocardial stunning greatly exceed those induced by a single ischemic episode.^{7 9 25 33 72 73} If regional perfusion is not measured simultaneously with regional contractile function, the protracted but ultimately reversible dysfunction associated with repetitive stunning may mimic myocardial hibernation.⁷⁴ With repetitive stunning, regional perfusion should recover while function remains depressed. With hibernation, as originally conceived, regional perfusion should be depressed and function should be depressed. Clinically, it is well known that many patients with coronary artery disease experience recurrent episodes of ischemia in the same territory, which may occur on a daily basis, so that the myocardium may remain reversibly depressed for extended periods of time. It is therefore possible that in some clinical cases in which reversible left ventricular dysfunction is thought to be secondary to hibernation, the depression of contractility is in fact secondary to repetitive episodes of stunning.⁷⁴

Effect of Age on Myocardial Stunning
In response to brief ischemia, myocardium from senescent animals is more susceptible to myocardial stunning and Ca²⁺ overload than that of young animals.^{75 76} The mechanism for this increased sensitivity to stunning and impaired ability to maintain Ca²⁺ homeostasis is uncertain and may be related to the accumulation of Ca²⁺ in the cytosol and nucleus, resulting in DNA nicking associated with endonuclease activation.⁷⁷ Whether these changes impair the synthesis of new contractile proteins to repair damaged myofilaments during the recovery phase of stunning is unknown and requires further investigation.

Myocardial Stunning in Humans
Myocardial stunning undoubtedly occurs in patients with coronary artery disease in a variety of situations in which the myocardium is exposed to transient ischemia, such as unstable angina, exercise-induced ischemia, acute myocardial infarction with early reperfusion, open heart surgery, and cardiac transplantation (as reviewed in References 74 and 78^{74 78} –80).

One clinical situation in which stunning has been observed is that of thrombolytic therapy. Several studies that measured global and/or regional left ventricular function did not observe initial dramatic improvement in function after thrombolytic therapy. Improvement in ventricular function occurred gradually over the course of a few weeks.^{81 82 83 84} One report⁸⁵ suggested that stunned myocardium could be recruited after thrombolytic therapy with small boluses of inotropes. These studies suggest that the ultimate return of cardiac function cannot be determined immediately after reperfusion. Assessment of function a few weeks after thrombolysis will provide a clearer picture as to whether salvaged tissue has recovered.

Stunned myocardium has been described in patients undergoing cardiac surgery. Despite the most modern cardioplegic techniques, some postsurgical stunning is common.^{86 87 88 89} Many patients require inotropic support and pressors for hours to days after surgery, which eventually can be weaned as the stunning abates.

Stunned myocardium occurs after exercise-induced ischemia in patients. Persistent wall-motion abnormalities were observed by echocardiography in patients with severe multivessel coronary artery disease at a time when chest pain and ST-segment deviations had resolved.⁹⁰ Ambrosio et al⁹¹ observed that persistent poststress regional wall-motion abnormalities were present at a time when regional perfusion had recovered. This finding of a flow-function dissociation is strong evidence in support of stunning as the mechanism for this postexercise left ventricular dysfunction. Fragasso et al⁹² showed that diastolic abnormalities could persist in some patients for a few days after an exercise test.

Angioplasty is a useful model for studying the heart's response to transient episodes of brief ischemia. Brief coronary occlusions (<60 seconds) induced at the time of angioplasty have been associated with persistent abnormalities in ventricular compliance.⁹³ Sheiban et al⁹⁴ induced longer periods of coronary artery occlusion (5 to 7 minutes) during angioplasty and observed that recovery of regional wall motion required 24 to 36 hours. Recovery in function was improved with calcium channel blockade.⁹⁴ These findings parallel the experimental observations described in animal models of brief coronary occlusion and reperfusion.

Stunning has been observed by echocardiography in patients with unstable angina.⁹⁵ In one study,⁸⁹ regional wall-motion abnormalities were observed immediately after angina and for at least a few hours after chest pain and ECG abnormalities had resolved.

An important clinical implication of stunning is that the phenomenon may contribute to heart failure. Some have postulated that stunning may play a role in ischemic cardiomyopathy.

However, the exact prevalence of this stunned myocardium in humans is unknown because of the difficulty in distinguishing myocardial stunning from other forms of reversible left ventricular dysfunction, such as those caused by silent ischemia and myocardial hibernation. A conclusive diagnosis of myocardial stunning (as opposed to silent ischemia or hibernation) requires simultaneous measurements of regional myocardial perfusion and function, which are rarely available.⁷⁴ Even when available, techniques for measuring regional perfusion in humans do not have sufficient resolution to discern transmural gradients of myocardial perfusion. This is a major limitation because subendocardial perfusion is the main determinant of transmural contractile function. Another confounding factor is that the coexistence of a subendocardial infarction with subepicardial stunning could be mistaken for hibernation because average transmural perfusion would be decreased.

The clinical situation is likely to be extremely complex, because recurrent bouts of severe ischemia (frequently silent) could be superimposed on a baseline of decreased perfusion, resulting in the superimposition of repetitive stunning on a baseline state of chronic hibernation.⁷⁴ In many patients with a severe coronary stenosis, the same myocardial region may contain an admixture of subendocardial scar and subendocardial viable myocardium in which stunning and hibernation can both occur, either in close temporal proximity or even simultaneously.⁷⁴

Future Directions
The members of the workshop identified a number of crucial areas for future investigation that can be grouped into two broad categories: experimental studies and clinical studies.

Experimental Studies
There is a need to integrate further the oxyradical and calcium hypotheses of myocardial stunning and also to augment understanding of the long-term consequences of brief ischemic episodes that cause stunning. Therefore, in experimental models, it will be important to accomplish the following:

1. To identify the precise myofilament lesion responsible for stunning, the mechanism that produces this lesion, and the mechanism whereby this lesion leads to impaired responsiveness to Ca²⁺ and to contractile dysfunction. Identification of the molecular basis of myocardial stunning would not only advance our understanding of the pathophysiology of ischemic heart disease but would also result in better preventive therapies.

2. To elucidate the role of Ca²⁺ overload in the genesis of myocardial stunning after regional ischemia (completely reversible or partly reversible ischemia) in vivo and after exercise-induced ischemia. If Ca²⁺ overload is causally involved in stunning, therapies aimed at preventing the rise in [Ca²⁺] should be developed.

3. To identify the source(s) of the ROS responsible for stunning, the relative contributions of different ROS to this phenomenon, and the precise mechanism whereby a short burst of ROS production results in prolonged depression of contractile function. Insights into these issues may result in the development of more efficacious antioxidant therapies.

4. To determine the mechanism of myocardial stunning after prolonged, partly reversible regional ischemia (subendocardial infarction) and after exercise-induced ischemia. The mechanism for stunning in these settings is presently unknown.

5. To develop experimental models of repetitive stunning and chronic hibernation. Use of these models should enable determination of whether repetitive stunning can be a cause of chronic left ventricular dysfunction mimicking hibernation and whether hibernation, defined as a primary decrease in coronary flow, does exist as a chronic condition.

6. To characterize the changes in gene regulation and receptor expression and function associated with stunning. It is now clear that brief, reversible ischemia has a significant effect on gene expression that is likely to result in significant phenotypic changes, particularly after repetitive bouts of ischemia. Given the fact that most patients with coronary disease have recurrent ischemic episodes, these studies would have great clinical relevance.

7. To elucidate the mechanism for the increased susceptibility of aged myocardium to stunning and to characterize the pathophysiology and pathogenesis of stunning in senescent hearts.

Human Studies
There is a need to transfer experimental concepts to the clinical setting. Therefore, in human studies it will be important to accomplish the following:

1. To elucidate the pathogenesis of stunning, particularly with regard to the role of myofilament dysfunction and oxidative stress. Little or nothing is known regarding the mechanism of stunning in patients. These studies should translate experimental findings to the clinical arena by testing in humans the pathogenetic hypotheses developed in animal models.

2. To develop better methods for the diagnosis of stunning in humans, including the development of diagnostic techniques that can rapidly distinguish stunning from necrosis after cardiac surgery and after revascularization for acute myocardial infarction. In these situations, such a distinction is essential for selecting the proper management of patients with severe left ventricular dysfunction or cardiogenic shock. Better diagnostic methods that can distinguish stunning from hibernation would also help to define the prevalence, natural history, and clinical importance of these two conditions; ideally, these diagnostic methods should be accurate, relatively inexpensive, and broadly available.

3. To define the natural history of disease progression, especially in the case of repetitive and exercise-induced stunning. Longitudinal follow-up of patients with these syndromes, coupled with serial measurements of regional myocardial function and perfusion, could elucidate whether recurrent or exercise-induced ischemia can result in persistent impairment of ventricular function simulating hibernation.

4. To develop efficacious treatments that can prevent or alleviate myocardial stunning. For the most part, the information acquired in experimental settings regarding the treatment and prevention of myocardial stunning has not yet been translated into clinically applicable therapies. Treatments aimed specifically at preventing myocardial stunning have not been developed in patients. These studies should clarify the usefulness of agents shown to be effective in experimental models (eg, antioxidants, adenosine,^{96 97 98} K_ATP channel openers,⁹⁹ Ca²⁺ antagonists,^{6 100 101 102} and angiotensin-converting enzyme inhibitors^{103 104} ) as preventive measures against myocardial stunning in such clinical settings as acute infarction with early revascularization, unstable angina, bypass surgery, and cardiac transplantation. Agents that are given during ischemia or at the time of reperfusion might prevent stunning. Other agents (infusion of inotropes) may improve function of the myocardium once it has been stunned; such therapy may be temporary and lasts only as long as the inotrope is infused. Inotropes given to myocardium that appears stunned may worsen ischemia in other areas of the heart if reperfusion or revascularization has not been complete.

	Hibernating Myocardium

Top Introduction Myocardial Stunning Hibernating Myocardium Preconditioning Summary Appendix References

 
The Concept of Hibernation
There is a subset of patients in whom left ventricular function improves significantly after coronary revascularization procedures.^{105 106} Such improvement can occur even in patients with chronic stable angina in whom there was no evidence of active ischemia at the time of revascularization. The functional improvement cannot simply be due to prevention of ongoing necrosis. These clinical observations have led to the concept that myocardium may adapt to chronic ischemia by decreasing its contractility, matching the reduced perfusion with reduced energy demand and thereby preserving viability (Fig 2A). If the ischemia is relieved, the myocardium regains normal contractility. From the earliest days of coronary artery bypass grafting, it was reported that impaired ventricular function was improved by operation.^{107 108} In l974, in studies at Brigham and Women's Hospital, Horn et al¹⁰⁹ pointed out that in patients with coronary artery disease and chronic asynergy, epinephrine infusion improved impaired regional wall motion. Postextrasystolic potentiation¹¹⁰ and exercise¹¹¹ also induced increases in contractility. Diamond et al¹¹² stated in 1978 that "reports of sometimes dramatic improvement in segmental left ventricular function following coronary bypass surgery, although not universal, leaves the clear implication that ischemic noninfarcted myocardium can exist in a state of function(al) hibernation." Rahimtoola^{105 106} aptly referred to hibernating myocardium as the persistently impaired function of viable myocardium in the setting of reduced coronary blood flow. In clinical studies, he observed progressive improvement in left ventricular wall-motion abnormalities after coronary artery bypass grafting in the absence of transmural necrosis. The concept of hibernating myocardium^{113 114 115} has stimulated extensive clinical and basic investigation.

View larger version (16K): [in this window] [in a new window]   Figure 2. Schematic showing two potential routes of hibernation.

Clinical Observations
There are numerous clinical studies that support the concept of hibernating myocardium. These studies show that left ventricular wall-motion abnormalities in patients with chronic angina were reversed by successful revascularization.^{107 108 116 117 118} In a classic case report, Rahimtoola¹⁰⁵ reported a patient with single-vessel coronary artery disease (occluded left anterior descending artery) who had a left ventricular ejection fraction of 37% and a large anteroapical region of akinesis on ventriculography. There had been no history of myocardial infarction. After administration of nitroglycerin, the regional wall-motion abnormality improved substantially. Eight months after coronary artery bypass surgery, the vein graft was patent, the regional wall-motion abnormality had fully resolved, and the ejection fraction had risen to 76%. Rankin et al¹¹⁹ showed that 34% of patients with chronic stable angina had improvement in left ventricular function after coronary artery bypass surgery. From 7 to 14 days after operation, there was an increase in global ejection fraction from 53% to 71%. Tillisch et al¹²⁰ showed with PET that they could identify areas of reduced perfusion that were metabolically active. After surgical revascularization, the majority of these segments recovered function. Cohen et al¹²¹ identified 12 patients with severe wall-motion abnormalities who had evidence of reversible ischemia and had improvements in global as well as regional wall motion immediately after PTCA.

Time Course of Recovery of Hibernating Myocardium
The time course of recovery of hibernating myocardium after revascularization has been variable. One study by Topol et al¹²² described nearly immediate improvement in regional wall-motion abnormalities after coronary artery bypass surgery. They used transesophageal echocardiography at the time of cardiac surgery to track changes in left ventricular function. Of 152 analyzed segments, there was an immediate improvement in systolic wall thickening from a prerevascularization value of 43% to a value of 52% (P<.001) after revascularization. As noted above, Cohen et al¹²¹ also observed immediate recovery of function after PTCA.

Nienaber et al¹¹⁷ observed improvements in left ventricular function after PTCA. They studied the effect of PTCA using PET scanning and two-dimensional echocardiography before PTCA, within 72 hours of revascularization, and late (67 to 68 days) after PTCA. Early postangioplasty images showed improvements in regional perfusion assessed by ¹³N-ammonia PET imaging. This was not accompanied by an early improvement in wall motion. However, segmental wall motion markedly improved on the late echocardiogram. This study suggested that although hibernating myocardium did recover function after revascularization, such recovery was not necessarily immediate. Baker et al¹²³ described the case of a patient who had evidence of hibernating myocardium due to compression of the coronary arteries by a ventricular pseudoaneurysm. Severe left ventricular dysfunction was documented by both radionuclide ventriculography and echocardiography. Thallium tomography revealed a perfusion defect in the anterior and anteroapical distribution of the left ventricle. After repair of the pseudoaneurysm and relief of compression on the coronary arteries, both regional and global function gradually returned toward normal over a 10-week period. One year after repair, thallium imaging showed normal perfusion and echocardiography showed normal function.

Thus, the recovery time of hibernating myocardium after revascularization has been variable. Immediate recovery of function might indicate that hibernation was acute, slow recovery over days to weeks might suggest subacute hibernation, and very slow recovery (months to years) might suggest that the hibernation was chronic.¹²⁴ Recovery time could be dependent on a number of factors, including duration of ischemia, severity of ischemia, degree of revascularization (complete versus partial), and amount of myocyte dedifferentiation within the hibernating zone. Recovery that occurs over days to weeks after revascularization of a hibernating segment might represent stunning. Recovery that occurs over a longer time period might represent the regeneration of myofibrils and repair of structural alterations that occurred during the chronic hibernating phase.

Studies described above and many others^{123 124 125 126 127 128 129 130 131 132 133 134} support the concept of hibernating myocardium as originally defined. However, one limitation of these clinical studies is that in general they do not track reduced flow and reduced function in a chronic manner, that is, at multiple time points before revascularization. Usually, they describe an acute "snapshot" view of the heart before revascularization. The terms "chronic flow reduction" and "chronic wall-motion abnormality" are often used in the description of hibernation, but it is not clear whether the wall-motion abnormalities and reductions of flow are truly chronic in all cases. Also, several PET studies in patients with left ventricular dysfunction observed relatively normal regional coronary blood flow in hibernating segments.^{135 136 137 138} Other groups have observed normal oxidative metabolism in these regions, suggesting that oxygen delivery to hibernating segments actually may be normal.¹³⁹ One area of active debate is whether hibernating myocardium in patients truly is characterized by reduced flow or normal flow with reduced coronary vasodilator reserve. Some of this debate may be related to the wide variation in what is reported as "normal" coronary flow in humans.

Detecting Hibernating Myocardium
Clinical experience has led to acceptance of the idea that hibernation is not only a "real" phenomenon but that it is also of compelling practical significance, at least in a subset of patients with critical coronary lesions. Much effort has gone into developing strategies to assess myocardial viability with a view to identifying those patients who are most likely to benefit from aggressive revascularization.¹⁴⁰ PET has led the way in this regard and has provided insight into the pathophysiology of the adaptation.^{141 142} In some studies, hibernating myocardium exhibits a characteristic switch from aerobic to anaerobic metabolism, as gauged by enhanced fluorodeoxyglucose uptake in the face of reduced blood flow detected by PET. Such myocardial segments tend to recover function after revascularization.¹⁴³

Other, more commonly available methods, notably thallium redistribution scintigraphy and dobutamine stress echocardiography, will probably turn out to have similar predictive accuracies.^{144 145} Thallium redistribution scintigraphy relies on the reasoning that coronary perfusion, although decreased, persists in the hibernating region; furthermore, the hibernating cells maintain membrane integrity and ion homeostasis so that they can accumulate the thallium. Tissue that does not accumulate thallium even with prolonged redistribution or after a secondary thallium infusion is not likely to be viable.^{146 147}

Dobutamine stress echocardiography assesses the contractile function of various myocardial segments. A region of the heart that functions poorly at baseline may not respond to dobutamine infusion at all (in which case it is nonviable) or may improve or worsen its contractility with the pressor challenge. Myocardium whose function improves with low-level dobutamine infusion but deteriorates with high-level infusion can be expected to improve with revascularization.^{148 149} If this indeed reflects the prototypical response of hibernating myocardium (as is commonly assumed), then hibernating myocardium retains both viability and the ability to respond to inotropic challenges.^{150 151}

More invasive approaches (eg, tissue sampling) are impractical clinically but yield additional clues as to the nature of the adaptation. Human hibernating myocardium has a distinctive histological appearance with myolysis, glycogen accumulation, and increased interstitial fibrosis (Fig 3).^{134 152 153 154} It has been suggested that these histopathological changes may represent a dedifferentiation of the myocytes.¹⁵³ When advanced, such changes indicate a poor prognosis for recovery even with adequate revascularization.¹⁵⁴

View larger version (163K): [in this window] [in a new window]   Figure 3. Light and electron microscopy of chronic hibernating myocardium. a and b, Light micrographs of moderately (a) and severely (b) altered myocardial areas. Red stain represents glycogen, which fills the myolytic cytosol. Note the more abundant glycogen stores in the severely affected cells and the accompanying increase in extracellular space (ES) in b. (Magnification x675.) c and d, Corresponding electron micrographs showing detailed structural remodeling in a moderately (c) and a severely (d) myolytic cardiomyocyte (CM). Glycogen (gl) is abundant; sarcomeres (sm) are present at the cell periphery; mitochondria (m) vary in size and shape (some are very small; arrows); the heterochromatin is uniformly distributed in the nucleus (n); and sarcoplasmic reticulum is virtually absent. These are characteristics of dedifferentiation. (a, magnification x8.820; b, x7.650.) Reproduced with permission from M. Borgers, Janssen Research Foundation, Beerse, Belgium.

Variable Chronicity of Hibernation
The original clinical descriptions of hibernating myocardium were based on the long-term recovery of function after revascularization (assessed several weeks or months after coronary artery bypass grafting).^{105 106} More recently, the variable chronicity of hibernation has been highlighted,^{117 122} leading to the hypothesis that the longer the ischemia, the slower the subsequent recovery.¹⁵⁵ Virtually all the animal models of hibernation have investigated the myocardial response to acute, low-grade ischemia,^{105 156 157} a situation that may or may not have common clinical correlates. The observation period is limited to several hours or days at most. In such models, there is a downregulation of contractile function roughly commensurate with the decrease in flow. Stunning generally ensues on the relief of the ischemia, complicating the interpretation of the recovery time course.¹⁵⁸ Such acute compensation to low-grade ischemia is not universally observed and, when it does occur, appears to be operative over a very limited perfusion range.¹⁰⁵ Nevertheless, the pathophysiology of such acute low-flow ischemia is consistent with the teleological notion that hibernating myocardium can downregulate its function (and thus its energy demand) so as to offset the otherwise lethal consequences of limited perfusion (Fig 2A).

The Concept of Metabolic Adaptation
There is debate as to whether the hibernating myocardium is truly ischemic or not. Some of this debate hinges on the definition of ischemia itself. If one defines the abnormality of contractility as a crucial component of the definition of ischemia, then hibernating tissue would be considered by some to be truly ischemic. However, if one defines ischemia as a reduction in blood flow severe enough to induce anaerobic metabolism, then hibernating tissue may not be truly ischemic, because there is evidence that hibernating myocardium has undergone a metabolic adaptation. Examples supporting the metabolic adaptation or metabolic "downregulation" theory of hibernating myocardium come from experimental studies. Animal models of short-term hibernation have shown that after placement of a partial coronary artery stenosis, there is a decrease in contractile function that correlates with a reduction in flow.^{156 157 159} Myocardial creatine phosphate content decreases during the first few minutes of ischemia induced by partial occlusion but then returns toward normal within 60 to 85 minutes.^{157 159} Fedele et al¹⁶⁰ showed that within 5 minutes after placement of a partial stenosis in an animal model of acute hibernation (in which necrosis did not occur), there was a significant reduction in anterior interventricular vein pH. However, by 180 minutes after stenosis placement, the pH had recovered to normal. In the same study, lactate consumption reversed to lactate production at 5 minutes after stenosis but then recovered toward lactate consumption by 120 minutes after stenosis. Thus, in the setting of ongoing hypoperfusion and contractile dysfunction, the myocardium remained viable and no longer appeared to be metabolically anaerobic. These experimental findings differ somewhat from PET studies in humans, which in some cases have shown increased fluorodeoxyglucose uptake in decreased zones of perfusion, suggesting continued anaerobic metabolism.

Canty¹⁶¹ pointed out that hibernating myocardium was characterized by a downregulation of regional myocardial oxygen consumption. He stated that "a key point is that the presence of both reductions in regional resting flow and oxygen consumption distinguish this adaptation from stunned myocardium."^{161 162 163}

Hibernation Versus Repetitive Stunning
Longer-term models of coronary stenosis have yielded results that suggest a fundamentally different mechanism for hibernation.⁷³ The central concept here is as follows: chronic coronary artery stenosis acts primarily to limit coronary reserve, not to decrease resting blood flow.¹³⁶ Episodes of spontaneous excitement and exercise then lead to repetitive cycles of ischemia precipitated by increased demand in the setting of limited flow reserve. When the ischemia is relieved, the myocardium remains dysfunctional despite having normal basal perfusion; essentially, it is chronically stunned.^{164 165} These observations have led to the proposal that hibernation is the result of repetitive cycles of ischemia and reperfusion (Fig 2B). In this view, cumulative stunning, not downregulation of function to counter chronic low-grade ischemia, leads to the distinctive phenotype of hibernating myocardium.^{73 149} There was considerable discussion related to this area at the workshop, and there were differences of opinion. Some investigators pointed out that there are a wealth of clinical examples and series of patients in which there is evidence of reduced blood flow at rest associated with regional dysfunction, both of which improve after revascularization. It is possible that there are subsets of patients who exhibit true hibernating (with reduced flow), some who exhibit repetitive stunning, and possibly some who exhibit both.^{74 145} This is clearly an area that will require additional research.

Future Directions
The basic biology of hibernation is less understood than either of the other conditions, ie, stunning and preconditioning; there is no universally accepted animal model, and thus the fundamental mechanisms remain largely unexplained. The situation here is exactly the opposite to that with stunning and preconditioning, both of which were laboratory-based discoveries that subsequently found clinical application. Hibernation, instead, is a clinical phenomenon of potentially immense importance that has proven difficult to study at the basic level.

Given these considerations, the members of the workshop recommended that future effort be concentrated on two areas. The first is to correct the deficiency of appropriate animal models for hibernating myocardium. Although it is recognized that no single animal model may be appropriate to address all of the questions relevant to hibernation, desirable features of such models include the following:

1. Validation of the model by generally accepted clinical criteria for hibernating myocardium: PET verification of increased glycolytic precursor uptake relative to blood flow, responsiveness to dobutamine, verification of the characteristic histological features, and demonstration of reversibility with reflow.¹⁶⁶

2. Exploration of the roles of multivessel disease and/or superimposed atherosclerosis in hibernation. This recommendation reflects the growing recognition that coronary atherosclerosis may have functional consequences that transcend those attributable solely to simple flow limitation.

3. Generation of appropriate small animal models of hibernation with high reproducibility.

4. Development of cellular models of hibernation. Such models could be used to investigate the pathogenesis of the histological lesions, including dedifferentiation, and of the metabolic adaptation, notably the switch from aerobic to anaerobic metabolism.

The second area deemed worthy of further focused study was in the clinical arena, in which several crucial issues regarding natural history and treatment remain to be explored. The following questions were highlighted as worthy subjects for future investigation:

1. What is the natural history of hibernating myocardium? Clinical studies are needed that look at more than just a snapshot view of perfusion and function at one time point before revascularization. Regional function, regional perfusion, and regional viability at multiple time points before revascularization are necessary to answer the question of whether segments of the ventricle truly hibernate as originally conceptualized.

2. What are the most effective (and most cost-effective) diagnostic and therapeutic strategies? Might medical therapy be a viable alternative to mechanical revascularization in some patients?

3. What is the relationship of hibernating myocardium to heart failure?¹⁶⁷ Does hibernating myocardium commonly underlie ischemic cardiomyopathy? How many segments of hibernating myocardium must be revascularized to substantially improve myocardial function?

4. Is there any benefit of revascularization of hibernating myocardium independent of the functional improvement?

	Preconditioning

Top Introduction Myocardial Stunning Hibernating Myocardium Preconditioning Summary Appendix References

 
Biology of Preconditioning
The term preconditioning was applied to the observation made in 1986 by Murry et al¹⁶⁸ that canine myocardium subjected to four brief episodes of ischemia and reperfusion would tolerate a more prolonged episode of ischemia better than myocardium not previously exposed to ischemia. Since that seminal observation in dogs, brief episodes of preconditioning ischemia consistently have been shown to reduce the size of experimentally induced myocardial infarction in rats, rabbits, pigs, and other species. Data from clinical studies suggest that preconditioning probably occurs in humans.¹⁶⁹ There is general agreement that other than early reperfusion, preconditioning is the strongest form of in vivo protection against myocardial ischemic injury.

There are certain limits to the benefits of preconditioning. The protection afforded by brief episodes of ischemia is transient and dissipates after 1 to 2 hours of reperfusion. In addition, if the duration of prolonged ischemia is very long (>90 minutes in some models), then the benefits of preconditioning are lost.¹⁷⁰ Of note is the observation that in some studies using rabbits, dogs, and rats, the benefits of preconditioning reappear when the interval between preconditioning ischemia and the prolonged ischemic episode is extended to 24 to 72 hours.^{171 172 173 174} A signature of preconditioned myocardium in the canine model is slowed ATP depletion and lactate accumulation during the sustained episode of ischemia.¹⁷⁵ This characteristic of slowed energy utilization by preconditioned tissue may be related to the mechanism whereby ischemic preconditioning delays cell death. Murry et al¹⁷⁵ pointed out that preconditioned tissue also exhibits a high creatine phosphate concentration, more intracellular glucose, less glycogen, and a smaller adenine nucleotide pool, contains more K+, and is somewhat edematous.

Although the definition of ischemic preconditioning was initially used to describe reduction in myocardial necrosis by brief episodes of preceding ischemia, the definition was extended to include protection against arrhythmias^{176 177} and postischemic left ventricular dysfunction (stunning).^{178 179} However, the efficacy of ischemic preconditioning in reducing arrhythmias and stunning has not been as consistent as its ability to reduce necrosis. Furthermore, it is unknown whether the protection afforded by preconditioning against arrhythmia and stunning is mediated by the same mechanism that mediates its protection against lethal cell injury.^{180 181}

Another term that has appeared in the literature related to preconditioning is "pharmacological preconditioning."^{182 183} This term refers to the ability of pharmacological agents given before coronary occlusion to reduce myocardial infarct size by stimulating the second messenger pathways thought to be involved in preconditioning, but without inducing ischemia. Examples of pharmacological preconditioning include administration of adenosine A₁ agonists and K_ATP channel openers. These agents have also been referred to as "preconditioning mimetics."¹⁶⁹

Mechanism of Preconditioning
Determination of the exact mechanism of ischemic preconditioning is important because if the mechanism can be elucidated, then better therapies (preconditioning mimetics) may be developed to treat a host of ischemic syndromes.

Role of Protein Kinase C
Downey and colleagues^{184 185 186 187} have proposed that in the rabbit, the mechanism of preconditioning involves stimulation of adenosine, bradykinin, and opioid receptors, which all couple through phospholipases to activate PKC, which then phosphorylates an unknown effector. Specifically, it was initially proposed that translocation of PKC from the cytosol (where it was inactive) to cellular membranes (where it became activated) constituted the memory for preconditioning.

A schematic of the cell signaling pathways followed during preconditioning is shown in Fig 4, as proposed by Downey. Adenosine receptors couple to G_i protein, which stimulates phospholipase (probably phospholipase D)¹⁸⁸ ; this in turn degrades membrane phospholipids to phosphatidic acid, which is converted to DAGs; the latter then activates PKC, which eventually phosphorylates some unknown effector, perhaps the sarcolemmal K_ATP channel. Once the K_ATP channel is activated, K⁺ exits the cells acting as a regional "cardioplegic"; the duration of action potential shortens, reducing energy demand. Studies supporting these hypotheses come from a series of experiments showing that in some models, antagonists of these various steps can block preconditioning, whereas agonists could mimic preconditioning.^{184 185 186 187} For example, the adenosine A₁ receptor agonist R(-)N⁶–(2-phenylisopropyl)-adenosine (PIA) reduced infarct size in the rabbit model in several laboratories.^{184 189} The adenosine antagonist 8-p-sulfophenyl theophylline (SPT) blocked preconditioning.¹⁸⁴ PKC blockers such as staurosporine, chelerythrine, and polymixin prevented preconditioning in rabbit hearts,¹⁸⁵ and calphostin C blocked it in the rat heart.¹⁹⁰ Isolated rabbit hearts were protected by direct activators of PKC such as phorbol esters and DAGs. Recent studies suggested that free radicals, which directly stimulate phospholipases in cells, also contribute to triggering preconditioning in the rabbit model.^{191 192 193} Evidence also suggests that at least one tyrosine kinase that also may be involved in the mechanism of preconditioning exists downstream from PKC in the rabbit heart.¹⁹⁴

View larger version (22K): [in this window] [in a new window]   Figure 4. Overall flow chart for the signal transduction system of preconditioning in the rabbit heart. Note that tyrosine kinase may also activate mitogen-activated protein kinase, causing expression of stress proteins and the second window of protection. PLC=phospholipase C; PLD=phospholipase D; PKC=protein kinase C; MAP=mitogen activated protein kinase. Reproduced with permission from J. Downey, University of South Alabama, Mobile.

Similar findings were observed in a model of isolated rabbit cardiomyocytes developed by Armstrong et al.^{195 196} They assessed myocyte injury as the rate of development of osmotic fragility during prolonged ischemic pelleting of cells incubated under oil. Protection of the cells was induced, after a brief ischemic preincubation,^{195 196} by adenosine, adenosine receptor agonists, bradykinin, angiotensin, and phenylephrine. Protection also occurred when the cells were preincubated with the phorbol ester PMA and the PKC activator ingenol. In addition, adenosine receptor antagonists, adenosine deaminase, and selective PKC inhibitors blocked the benefit of ischemic preconditioning.

Other Cellular Mediators
Although activation and translocation of PKC is perhaps the most popular and attractive theory to explain infarct size reduction with preconditioning, there are other hypotheses that have been put forward. One of these, advocated by Kitakaze and colleagues,¹⁹⁷ involves activation of 5'-nucleotidase, the enzyme responsible for dephosphorylation of AMP to form adenosine, which would then be protective. A second, alternate hypothesis is that calcium influx during the preconditioning stimulus, perhaps via Na⁺-H⁺ and Na⁺-Ca²⁺ exchange, is important in eliciting cardioprotection.¹⁹⁸

There is, however, controversy regarding virtually all aspects of the proposed cellular mediators of preconditioning downstream from the initial stimulation of G protein–coupled receptors. For example, Przyklenk et al^{199 200} concluded that activation of 5'-nucleotidase is not required to elicit cardioprotection, whereas Ovize and colleagues²⁰¹ reported that pharmacological inhibition of tyrosine kinase limited infarct size in control myocardium but failed to block the protective effects of preconditioning. Similarly, Shipolini et al²⁰² failed to confirm the concept that Na⁺-H⁺ exchange might play a role in preconditioning-induced protection.

Arguments For and Against the Role of PKC
Without doubt, the most hotly debated potential mediator of preconditioning is PKC. Evidence in support of the PKC hypothesis was largely derived from administration of PKC agonists and antagonists in the rabbit and rat models. However, PKC inhibitors failed to attenuate preconditioning in the dog²⁰³ and pig,^{204 205} whereas brief preischemic infusion of PMA did not limit infarct size in the porcine heart.²⁰⁴ When biochemical quantitation as well as fluorescence confocal microscopy was used, PKC translocation was not observed during brief episodes of preconditioning ischemia in the canine heart.²⁰³ However, translocation was observed with longer coronary occlusions and with PMA injections.

Although these observations in the canine and porcine models argue against the role of PKC in ischemic preconditioning, interpretation of both pharmacological and biochemical results may be confounded by limitations in methodology; ie, few PKC inhibitors are selective for PKC alone, and if only one of the 12 isoenzymes of PKC identified to date is important in eliciting protection, measurement of total PKC activity may not reflect the subtle alterations in the subcellular distribution of the one crucial isoenzyme. It is even possible that unidentified receptors may exist in dog or pig that enter the signal transduction pathway downstream of PKC, bypassing it. Quantitative assessment of the activity and distribution of PKC isoenzymes in response to both pharmacological manipulation and ischemic preconditioning per se may be required to resolve this controversy conclusively. In this regard, recent studies have documented isoform-selective translocation of PKC in response to preconditioning stimuli,^{206 207 208} in some instances with no change in total PKC activity.²⁰⁶ Isoform-selective translocation of PKC- was observed in isolated rat hearts (immunohistochemistry²⁰⁸ ), of PKC- and - in isolated rat neonatal cardiomyocytes,²⁰⁷ and of PKC- and - with no change in the subcellular distribution of total PKC activity in conscious rabbits (Western immunoblotting),²⁰⁶ suggesting that the mechanism of preconditioning might involve selective activation of one or few isozymes. However, even the conclusive identification of isoform-selective PKC translocation may be unable to definitively resolve the controversy because the isoform-specific antibodies often used in these studies are limited by their inability to distinguish whether the isoform is active or inactive.²⁰⁹

Another emerging concept that may be relevant to the mechanism of ischemic preconditioning is that protein phosphatase inhibition appears to protect isolated rabbit cardiomyocytes even when added late in the prolonged ischemic phase.²¹⁰

Role of Potassium Channels
A final proposed mediator of infarct-size reduction is the ATP-sensitive potassium channel (K_ATP). Specifically, Gross and colleagues^{211 212} have shown that the K_ATP channel is important for preconditioning in the canine model. Intravenous glibenclamide, a K_ATP channel antagonist, given either before or after a single 5-minute period of ischemic preconditioning, abolished the protective effect afforded by preconditioning in reducing infarct size in the canine model.²¹¹ The nonsulfonylurea K_ATP channel blocker sodium 5-hydroxydecanoate (5-HD) antagonized the protective effect of preconditioning without affecting infarct size in nonpreconditioned hearts.²¹² These investigators have also shown that a number of K_ATP channel openers (nicorandil, pinacidil, and bimakalin) are capable of mimicking the effects of ischemic preconditioning. Activation of a variety of receptors (adenosine, acetylcholine, bradykinin, and others) that can mimic the cardioprotective effects of ischemic preconditioning may involve the K_ATP channel, because glibenclamide and 5-HD were shown to block the cardioprotective effects of these agents.^{213 214}

However, not all studies have implicated K_ATP channels in preconditioning. Some studies in rabbit hearts, isolated rabbit cardiomyocytes, and rats have not confirmed the importance of K_ATP channels in preconditioning.^{215 216 217} A recent study²¹⁸ suggested that the K_ATP channel blocker glibenclamide, which is often used in these models, must be administered well before the coronary occlusion to block the effect of preconditioning. Although an initial hypothesis was that stimulation of K_ATP channels might work by shortening the action potential duration and slowing the utilization of ATP, not all studies have documented a shortening of the action potential, and the mitochondrial K_ATP channels possibly play a role.

The exact final effector mechanisms of preconditioning remain to be elucidated. We do not know what factors exactly explain the resistance to ischemia after preconditioning ischemia. The slowed rate of ATP fall observed in preconditioned tissue could be a consequence rather than a mechanism of preconditioning. If it is a mechanism, why is it transient, only lasting for 10 to 20 minutes during ischemia? It remains to be determined whether the protection is due to preservation of energy stores. Alternatively, the brief episodes of ischemia might limit production of oxidants during a subsequent long ischemia, resulting in protection of membranes. Considerable work is needed to better define the end-effector mechanism of ischemic preconditioning.

Second Window
The second window of protection was described by Yellon and Baxter²¹⁹ and Kuzuya et al¹⁷² as enhanced tolerance to lethal ischemia 24 hours after a preconditioning stimulus of brief repetitive episodes of ischemia.²¹⁹ The phenomenon of late reappearance of the protective effect of preconditioning has been observed in open chest rabbit and dog and chronically instrumented conscious rabbit and rat.^{172 219 220 221} Recent work suggests that the delayed anti-infarct effect of preconditioning may extend over a period of 1 to 3 days, unlike the early period of protection by classic preconditioning, which is lost within a few hours.²²² The mechanism of the delayed effect of preconditioning is under investigation. The time delay may allow activation of genes and expression of new proteins that could play a role in the late protection. It is unlikely that expression of new proteins plays a role in the early protection after ischemic preconditioning. It is possible that an entirely different set of triggers and signaling pathways is important to the second window. Some of the mechanism that are being studied include expression of heat shock protein (HSP70), alterations in the activity of superoxide dismutase, induction of inducible nitric oxide synthase, and involvement of PKC.^{221 223 224 225} Recently, Bolli et al showed that brief episodes of ischemic preconditioning can protect the porcine and rabbit heart from an episode of stunning 24 hours or more after the preconditioning episode²²⁶ and that this protection is triggered by the generation of oxyradicals²²⁷ and nitric oxide.²²⁸ In addition, they demonstrated that in the conscious rabbit, the delayed protection against infarction is also triggered by the generation of nitric oxide during the initial preconditioning ischemia.²²⁹ This "second window" of protection against infarction is not, however, seen in the pig model.²³⁰

Stunning Versus Preconditioning
Stunning and preconditioning have similarities in that both phenomena involve brief episodes of ischemia followed by reperfusion. One initial thought regarding the mechanism of preconditioning was that the myocardium, having been stunned by a brief period of ischemia, would have reduced contractility and hence reduced oxygen demand, rendering it more resistant to subsequent ischemia. This concept turned out to be incorrect. First, the myocardial oxygen demand of stunned myocardium has not been reduced in most studies.²³¹ Also, Murry et al²³² studied the temporal relationship between preconditioning and stunning. They observed that one 15-minute coronary occlusion separated by 5 minutes of reperfusion markedly reduced infarct size induced by a 40-minute occlusion. If the reperfusion phase between the brief preconditioning ischemia and 40-minute occlusion was extended to 120 minutes, the myocardium remained severely stunned after the brief ischemia, but the myocardial infarct size plotted against collateral flow returned toward nonpreconditioned values. In another study, Matsuda et al²³³ showed that dobutamine could be used to reverse stunning induced by four 5-minute coronary occlusions in the dog model but that reversing stunning did not prevent preconditioning. Conversely, as already described in regional models of coronary occlusion/reperfusion, classic ischemic preconditioning does not reduce acute stunning.¹⁵⁹

Therefore, although brief periods of ischemia induce both stunning and preconditioning, the two phenomena can be dissociated, and preconditioning is not due to simply reduced contractile function of stunned myocardium.

Clinical Evidence for Preconditioning
The most direct evidence that human myocardium can be preconditioned comes from studies performed in isolated, cultured human cardiomyocytes subjected to simulated ischemia and reperfusion. Ikonomidis et al²³⁴ showed that prior brief episodes of ischemia improved survival when cultured human cardiac myocytes were exposed to 90 minutes of sustained ischemia. Studies of human myocardium obtained at the time of cardiac surgery have demonstrated better preservation of ATP during 10-minute periods of aortic cross-clamp fibrillation when hearts were exposed to prior 3-minute episodes of ischemia.²³⁵ In addition, in the same model, it has recently been shown that troponin release is significantly attenuated in patients who had been preconditioned previously.²³⁶ Studies using human cardiac muscle (atrial trabeculae) confirm findings in the animal laboratory with respect to initiation of preconditioning with hypoxia and the adenosine A₁ agonist rPIA.²³⁷ Furthermore, the signaling pathways in human cardiac muscle appear to involve PKC, with supporting evidence for the role of the K_ATP channel as a positive end effector.²³⁸

Repeated coronary artery occlusions in the course of PTCA may simulate the preconditioning phenomenon. Several clinical studies have observed progressive decreases in chest pain, ST-segment elevation, and lactate production on subsequent compared with first 60- to 90-second intracoronary balloon inflation.^{239 240} The potassium channel blocker glibenclamide can prevent the beneficial effects of repeated balloon angioplasty. Adenosine can mimic the protective effect,²⁴¹ whereas adenosine antagonists block it,^{242 243} findings that parallel experimental observations in the animal laboratory. Some studies that assessed collateral flow showed no evidence of recruitment during sequential balloon inflations,²³⁹ although one study²⁴⁰ did report that in about half of the patients, there was recruitment.

A number of clinical studies have shown that preinfarct angina may confer benefit in acute myocardial infarction, including smaller infarct size assessed by enzymes or ECG, better in-hospital survival, less in-hospital heart failure and shock, better left ventricular function, and lower rate of arrhythmia.^{244 245 246} In the recent TIMI 9 trial,²⁴⁷ preinfarction angina reduced the combined end point of 30-day mortality, heart failure, and recurrent myocardial infarction, but only when the preinfarct angina occurred within 24 hours of infarction. Ishihara et al²⁴⁸ showed that patients with prodromal angina within 24 hours of infarction had an improved 5-year survival. Although ischemic preconditioning is one potential mechanism whereby preinfarct angina confers benefits to infarct patients, other potential mechanisms include earlier and more complete thrombolysis, which has been observed in one study²⁴⁹ and may imply a preconditioning-like effect on the vasculature, and the development of intramural collaterals that are not detected by coronary angiography.

Patients with coronary artery disease have been observed to exercise longer before developing angina and may develop less angina and ischemia during a second exercise test compared with a first test when these tests are separated by a brief rest period.^{250 251} The clinical observation of the "warm-up" phenomenon may represent one aspect of preconditioning in humans.

Mentzer²⁵² and colleagues have applied the pharmacological preconditioning concept to patients undergoing open heart surgery. Placebo and various doses of adenosine (100 µmol/L, 1 mmol/L, 2 mmol/L, and a 2 mmol/L plus a 6-minute 140 µg · kg^-1 · min^-1 pretreatment infusion) were administered to patients before cardiopulmonary bypass. Patients were hemodynamically monitored before, during, and after dosing, before being placed on cardiopulmonary bypass, after weaning from bypass, and then for 24 hours. Transesophageal echocardiography was performed before bypass, after bypass, and during the postoperative stay. The results showed that adenosine was safe and well tolerated in the doses used. The patients receiving high-dose adenosine required significantly less or no vasoactive drugs during the first 24 hours after heart surgery and had improved average regional wall motion by echocardiography. This is one of the first trials to apply pharmacological preconditioning directly to humans to try to improve outcomes. There have been anecdotal reports of actually inducing ischemic preconditioning (by transiently clamping a coronary artery and then reperfusing) before minimally invasive directed coronary artery bypass.

Future Directions
The members of the workshop suggested studies within three general areas: mechanism of preconditioning, the biology of preconditioning, and clinical studies.

Mechanism of Preconditioning
If preconditioning mimetic pharmaceuticals are going to be developed for the clinical treatment of ischemia, then it is crucial to learn the mechanisms of preconditioning.

1. There is a need to develop models allowing assessment of intracellular signaling pathways in preconditioning and determination of the final effector(s). These models will require multidisciplinary approaches and should be designed to help resolve the roles of suggested signaling pathways, including but not limited to PKC, 5'-nucleotidase, adenosine A₃ receptors, and K_ATP channels. Small-animal models (ie, rabbit) may rely on PKC-dependent signaling, whereas large animals (dog, pig) may rely on K_ATP and other mechanisms that may be independent of PKC.

2. There is a need to clarify the mechanism of the second window (or late phase) of ischemic preconditioning. Very little is known regarding the mechanism of the second window.

3. Because it is unknown which mechanisms are most important in humans, it would be prudent to include whole animal models of both small and large animals. Isolated myocyte models in humans and in large and small animals should also be developed.

Biology of Preconditioning
There is a need to characterize further the short-term and long-term "biology" of preconditioning. With the use of large- and small-animal models and cell-based models, studies should be specifically designed to accomplish the following:

1. Ascertain whether metabolic changes (such as slower rate of ATP degradation and attenuation of acidosis) and improvement in cell volume regulation are mere markers of preconditioning or are necessary for protection.

2. Determine whether preconditioning is effective or altered in aged and diseased hearts.

3. Establish the long-term consequences of preconditioning on left ventricular remodeling, infarct expansion, and survival.

4. Elucidate the properties of the "second window of protection," particularly in large-animal models.

5. Determine whether preconditioning exerts a beneficial effect on arrhythmias and the vasculature, including the recent concept that a preconditioned vessel may be more amenable to thrombolysis.

Clinical Studies of Preconditioning
There is a need for well-designed clinical trials to test ischemic preconditioning agonists (or mimetics) such as adenosine, A₁ and A₃ agonists, and/or K_ATP channel openers, administered either acutely before an ischemic event or 24 hours before planned ischemia (mimicking the second window of protection). Suggested clinical arenas for studies should include (1) angioplasty (a useful setting for initial screening of potential mimetics), (2) coronary artery bypass grafting and other open heart surgery, (3) minimally invasive directed coronary artery bypass (MIDCAB), (4) preconditioning of a donor transplant heart, and (5) unstable and stable angina.

	Summary

Top Introduction Myocardial Stunning Hibernating Myocardium Preconditioning Summary Appendix References

 
During the last 15 years, the concepts of stunning, hibernating, and preconditioning have emerged as new phenomena that relate to myocardial ischemia/reperfusion. Stunning and hibernation have the potential to contribute to heart failure, and clinicians are becoming increasingly aware of these phenomena. In particular, preconditioning has the potential to lead to new therapies for a variety of ischemic syndromes. The participants at this NHLBI workshop strove to consider numerous factors in producing a list of promising yet practical opportunities to advance our understanding of these ischemic conditions. The recommendations emerging from the workshop are designed as a guide to the NHLBI's Heart Research Program in planning support of studies addressing stunning, hibernation, and preconditioning and their roles in ischemia, heart failure, and arrhythmia. It is hoped that future efforts in this area will ultimately improve the national cardiovascular health.

	Appendix

Top Introduction Myocardial Stunning Hibernating Myocardium Preconditioning Summary Appendix References

 
Participants in the Workshop
Eugene Braunwald, MD, Workshop Chairman, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Leslie J. Reinlib, PhD, Workshop Coordinator, National Heart, Lung, and Blood Institute, Bethesda, Md; Roberto Bolli, MD, Workshop Co-Chairman, University of Louisville, Louisville, Ky; Robert A. Kloner, MD, PhD, Workshop Co-Chairman, University of Southern California, Good Samaritan Hospital, Los Angeles; Eduardo Marban, MD, PhD, Workshop Co-Chairman, Johns Hopkins University, Baltimore, Md; Robert O. Bonow, MD, Northwestern University Medical School, Chicago, Ill; Marcel Borgers, PhD, Janssen Research Foundation, Beerse, Belgium; James Downey, PhD, University of South Alabama, Mobile; Harvey Feigenbaum, MD, Indiana University, Indianapolis; Charles Ganote, MD, Quillen College of Medicine, Johnson City, Tenn; Garrett Gross, PhD, Medical College of Wisconsin, Milwaukee; Robert Jennings, MD, Duke University Medical Center, Durham, NC; Sidney Levitsky, MD, Harvard Medical School, Boston, Mass; James D. McCully, PhD, Harvard Medical School, Boston, Mass; Robert Mentzer, Jr, MD, University of Kentucky Medical Center, Lexington; William P. Miller, MD, University of Wisconsin, Madison; Karin Przyklenk, PhD, Good Samaritan Hospital, Los Angeles, Calif; Shahbudin Rahimtoola, MD,* University of Southern California, Los Angeles; Stephen Vatner, MD, Allegheny University of the Health Sciences, Pittsburgh, Pa; and Derek Yellon, DSc, HonMRCP, FESC, The Hatter Institute, University College London Hospital and Medical School, London, United Kingdom.

*Participated in workshop; elected not to participate in preparation of manuscript.

	Selected Abbreviations and Acronyms

 

DAG = diacylglycerol PET = positron emission tomography PKC = protein kinase C PMA = phorbol myristate acetate PTCA = percutaneous transluminal coronary angioplasty ROS = reactive oxygen species

	Footnotes

 
A list of workshop participants appears in the Appendix. Correspondence to Robert A. Kloner, MD, PhD, Heart Institute Research Laboratory, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017.

	References

Top Introduction Myocardial Stunning Hibernating Myocardium Preconditioning Summary Appendix References

 
1. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–1149.[Abstract/Free Full Text]

2. Bolli R. Mechanism of myocardial `stunning.' Circulation. 1990;82:723–738.[Abstract/Free Full Text]

3. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner F. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975;56:978–985.

4. Heyndrickx GR, Baig H, Nellens P, Leusen I, Fishbein MC, Vatner SF. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol. 1978;234:H653–H659.[Abstract/Free Full Text]

5. Bolli R, Zhu WX, Thornby JI, O'Neill PG, Roberts R. Time-course and determinants of recovery of function after reversible ischemia in conscious dogs. Am J Physiol. 1988;254:H102–H114.[Abstract/Free Full Text]

6. Przyklenk K, Kloner RA. Effect of verapamil on postischemic `stunned' myocardium: importance of the timing of treatment. J Am Coll Cardiol. 1988;11:614–623.[Abstract]

7. Nicklas JM, Becker LC, Bulkley BH. Effects of repeated brief coronary occlusion on regional left ventricular function and dimension in dogs. Am J Cardiol. 1985;56:473–478.[Medline] [Order article via Infotrieve]

8. Stahl LD, Aversano TR, Becker LC. Selective enhancement of function of stunned myocardium by increased flow. Circulation. 1986;74:843–851.[Abstract/Free Full Text]

9. Bolli R, Zughaib M, Li X-Y, Tang X-L, Sun J-Z, Triana JF, McCay P. Recurrent ischemia in the canine heart causes recurrent bursts of free radical production that have a cumulative effect on contractile function: a pathophysiological basis for chronic myocardial `stunning.' J Clin Invest. 1995;96:1066–1084.

10. Stahl LD, Weiss HR, Becker LC. Myocardial oxygen consumption, oxygen supply/demand heterogeneity, and microvascular patency in regionally stunned myocardium. Circulation. 1988;77:865–872.[Abstract/Free Full Text]

11. Cohen MV, Downey JM. Myocardial stunning in dogs: preconditioning effect and influence of coronary collateral flow. Am Heart J. 1990;120:282–291.[Medline] [Order article via Infotrieve]

12. Lavallee M, Cox D, Patrick TA, Vatner SF. Salvage of myocardial function by coronary artery reperfusion 1, 2, and 3 hours after occlusion in conscious dogs. Circ Res. 1983;53:235–247.[Abstract/Free Full Text]

13. Bush LR, Buja LM, Samowitz W, Rude RE, Wathen M, Tilton GD, Willerson JT. Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs: comparison of 2- and 4-hour occlusions. Circ Res. 1983;53:248–263.[Free Full Text]

14. Kusuoka H, Porterfield JK, Weisman HF, Weisfeldt ML, Marban E. Pathophysiology and pathogenesis of stunned myocardium: depressed Ca²⁺ activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts. J Clin Invest. 1987;79:950–961.

15. Kusuoka H, Koretsune Y, Chacko VP, Weisfeldt ML, Marban E. Excitation-contraction coupling in postischemic myocardium: does failure of activator Ca²⁺ transients underlie stunning? Circ Res. 1990;66:1268–1276.[Abstract/Free Full Text]

16. Marban E, Kitakaze M, Kusoka H, Porterfield JK, Yue DT, Chacko VP. Intracellular free calcium concentration measured with¹⁹F NMR spectroscopy in intact ferret hearts. Proc Natl Acad Sci U S A. 1987;84:6005–6009.[Abstract/Free Full Text]

17. Marban E, Kitakaze M, Koretsune Y, Yue DT, Chacko VP, Pike MM. Quantification of [Ca²⁺]_i in perfused hearts: critical evaluation of the 5F-BAPTA and nuclear magnetic resonance method as applied to the study of ischemia and reperfusion. Circ Res. 1990;66:1255–1267.[Abstract/Free Full Text]

18. Ambrosio G, Weisfeldt ML, Jacobus WE, Flaherty JT. Evidence for a reversible oxygen radical–mediated component of reperfusion injury: reduction by recombinant human superoxide dismutase administered at the time of reflow. Circulation. 1987;75:282–291.[Abstract/Free Full Text]

19. Ambrosio G, Zweier JL, Jacobus WE, Weisfeldt ML, Flaherty JT. Improvement of postischemic myocardial function and metabolism induced by administration of desferrioxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation. 1987;76:906–915.[Abstract/Free Full Text]

20. Gardner TJ. Oxygen radicals in cardiac surgery. Free Radic Biol Med. 1988;4:45–50.[Medline] [Order article via Infotrieve]

21. Stewart JR, Blackwell WH, Crute SL, Loughlin V, Greenfield LJ, Hess ML. Inhibition of surgically induced ischemia/reperfusion injury by oxygen free radical scavengers. J Thorac Cardiovasc Surg. 1983;86:262–272.[Abstract]

22. Johnson DL, Horneffer PJ, Dinatale JM Jr, Gott VL, Gardner TJ. Free radical scavengers improve functional recovery of stunned myocardium in a model of surgical coronary revascularization. Surgery. 1987;102:334–340.[Medline] [Order article via Infotrieve]

23. Illes RW, Silverman NA, Krukenkamp IB, del Nido PJ, Levitsky S. Amelioration of postischemic stunning by deferoxamine-blood cardioplegia. Circulation. 1989;80(suppl III):III-30–III-35.

24. Homans DC, Sublett E, Dai XZ, Bache RJ. Persistence of regional left ventricular dysfunction after exercise-induced myocardial ischemia. J Clin Invest. 1986;77:66–73.

25. Homans DC, Laxon DD, Sublett E, Lindstrom P, Bache RJ. Cumulative deterioration of myocardial function after repeated episodes of exercise-induced ischemia. Am J Physiol. 1989;256(Heart Circ Physiol 25):H1462–H1471.

26. Hittinger L, Shannon RP, Kohin S, Manders WT, Kelly P, Vatner SF. Exercise-induced subendocardial dysfunction in dogs with left ventricular hypertrophy. Circ Res. 1990;66:329–343.[Abstract/Free Full Text]

27. Bolli R. Oxyradicals in the pathogenesis of myocardial stunning. In: Heyndrickx GR, Vatner SF, Wijns W, eds. Stunning, Hibernation, and Preconditioning: Clinical Pathophysiology of Myocardial Ischemia. Philadelphia, Pa: Lippincott-Raven Press; 1997:205–228.

28. Kusuoka H, Marban E. Cellular mechanism of myocardial stunning. Annu Rev Physiol. 1992;54:243–256.[Medline] [Order article via Infotrieve]

29. Marban E, Koretsune Y, Corretti M, Chacko VP, Kusoka H. Calcium and its role in myocardial cell injury during ischemia and reperfusion. Circulation. 1989;80(suppl IV):IV-17–IV-22.

30. Myers ML, Bolli R, Lekich RF, Hartley CJ, Roberts R. Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia. Circulation. 1985;72:915–921.[Abstract/Free Full Text]

31. Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the `stunned' myocardium. Circ Res. 1986;58:148–156.[Abstract/Free Full Text]

32. Gross GJ, Farber NE, Hardman HF, Warltier DC. Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am J Physiol. 1986;250:H372–H377.

33. Sun J-Z, Tang X-L, Park S-W, Qiu Y, Turrens J, Bolli R. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest. 1996;97:562–576.[Medline] [Order article via Infotrieve]

34. Shlafer M, Cane PF, Kirsh MM. Superoxide dismutase plus catalase enhances the efficacy of hypothermic cardioplegia to protect the globally ischemic, reperfused heart. J Thorac Cardiovasc Surg. 1982;83:830–839.[Abstract]

35. Menasche P, Grossest C, Gauduel Y, Piwnica A. A comparative study of free radical scavengers in cardioplegic solutions: improved protection with peroxidase. J Thorac Cardiovasc Surg. 1986;92:264–271.[Abstract]

36. Ytrehus K, Gunnes S, Myklebust R, Mjos OD. Protection by superoxide dismutase and catalase in the isolated rat heart reperfused after prolonged cardioplegia: a combined study of metabolic, functional and morphometric ultrastructural variables. Cardiovasc Res. 1987;21:492–499.[Medline] [Order article via Infotrieve]

37. Bolli R. Role of oxygen radicals in myocardial stunning. In: Kloner RA, Przyklenk K, eds. Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations. New York, NY: Marcel Dekker; 1993:155–195.

38. Triana JF, Li XY, Jamaluddin U, Thornby JI, Bolli R. Postischemic myocardial `stunning': identification of major differences between the open-chest and the conscious dog and evaluation of the oxygen radical hypothesis in the conscious dog. Circ Res. 1991;69:731–747.[Abstract/Free Full Text]

39. Sekili S, McCay PB, Li X-Y, Zughaib M, Sun JZ, Tang X-L, Thornby JI, Bolli R. Direct evidence that the hydroxyl radical plays a pathogenetic role in myocardial `stunning' in the conscious dog and that stunning can be markedly attenuated without subsequent adverse effects. Circ Res. 1993;73:705–723.[Abstract/Free Full Text]

40. Jeroudi MO, Triana FJ, Patel BS, Bolli R. Effect of superoxide dismutase and catalase, given separately, on myocardial `stunning.' Am J Physiol. 1990;259:H889–H901.[Abstract/Free Full Text]

41. Buchwald A, Klein HH, Lindert S, Pich S, Nebendahl K, Wiegand V, Kreuzer H. Effect of intracoronary superoxide dismutase on regional function in stunned myocardium. J Cardiovasc Pharmacol. 1989;13:258–264.[Medline] [Order article via Infotrieve]

42. Koerner JE, Anderson BA, Dage RC. Protection against postischemic myocardial dysfunction in anesthetized rabbits with scavengers of oxygen-derived free radicals: superoxide dismutase plus catalase, N-2-mercaptopropionyl glycine and captopril. J Cardiovasc Pharmacol. 1991;17:185–191.[Medline] [Order article via Infotrieve]

43. Bolli R, Jeroudi MO, Patel BS, Aruoma OI, Halliwell B, Lai EK, McCay PB. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: evidence that myocardial `stunning' is a manifestation of reperfusion injury. Circ Res. 1989;65:607–622.[Abstract/Free Full Text]

44. Bolli R, Patel BS, Jeroudi MO, Lai EK, McCay PB. Demonstration of free radical generation in `stunned' myocardium of intact dogs with the use of the spin trap A-phenyl N-tert-butyl nitrone. J Clin Invest. 1988;82:476–485.

45. Bolli R, Jeroudi MO, Patel BS, DuBose CM, Lai EK, Roberts R, McCay PB. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A. 1989;86:4695–4699.[Abstract/Free Full Text]

46. Bolli R, Patel BS, Jeroudi MO, Li XY, Triana JF, Lai EK, McCay PB. Iron-mediated radical reactions upon reperfusion contribute to myocardial `stunning.' Am J Physiol. 1990;259:H1901–H1911.[Abstract/Free Full Text]

47. Li XY, McCay PB, Zughaib M, Jeroudi MO, Triana JF, Bolli R. Demonstration of free radical generation in the `stunned' myocardium in the conscious dog and identification of major differences between conscious and open-chest dogs. J Clin Invest. 1993;92:1025–1041.

48. Sun JZ, Kaur H, Halliwell B, Li XY, Bolli R. Use of aromatic hydroxylation of phenylalanine to measure production of hydroxyl radicals after myocardial ischemia in vivo: direct evidence for a pathogenetic role of the hydroxyl radical in myocardial stunning. Circ Res. 1993;73:534–549.[Abstract/Free Full Text]

49. Homans DC, Asinger R, Pavek T, Crampton M, Lindstrom P, Peterson D, Bache RJ. Effect of superoxide dismutase and catalase on regional dysfunction after exercise-induced ischemia. Am J Physiol. 1992;263:H392–H398.[Abstract/Free Full Text]

50. Hearse DG. Stunning: a radical review. In: Opie LH, ed. Stunning, Hibernation, and Calcium in Myocardial Ischemia and Reperfusion. Boston, Mass: Kluwer Academic Press; 1992:10–55.

51. O'Neill PG, Charlat ML, Michael LH, Roberts R, Bolli R. Influence of neutrophil depletion on myocardial function and flow after reversible ischemia. Am J Physiol. 1989;256:H341–H351.[Abstract/Free Full Text]

52. Bolli R. Role of neutrophils in myocardial stunning after brief ischaemia: the end of a six-year-old controversy (1987–1993). Cardiovasc Res. 1993;27:728–730.[Medline] [Order article via Infotrieve]

53. Dage RC, Anderson BA, Mao SJT, Koerner JE. Probucol reduces myocardial dysfunction during reperfusion after short-term ischemia in rabbit heart. J Cardiovasc Pharmacol. 1991;17:158–165.[Medline] [Order article via Infotrieve]

54. Kaneko M, Beamish RE, Dhalla NS. Depression of heart sarcolemmal Ca²⁺-pump activity by oxygen free radicals. Am J Physiol. 1989;256:H368–H374.[Abstract/Free Full Text]

55. Kaneko M, Elimban V, Dhalla NS. Mechanism for depression of heart sarcolemmal Ca²⁺ pump by oxygen free radicals. Am J Physiol. 1989;257:H804–H811.[Abstract/Free Full Text]

56. Kim M-S, Akera T. O₂ free radicals: cause of ischemia-reperfusion injury to cardiac Na⁺-K⁺-ATPase. Am J Physiol. 1987;252:H252–H257.[Abstract/Free Full Text]

57. Reeves JP, Bailey CA, Hale CC. Redox modification of sodium-calcium exchange activity in cardiac sarcolemmal vesicles. J Biol Chem. 1986;261:4948–4955.[Abstract/Free Full Text]

58. Gao WD, Liu Y, Marban E. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle: implications for the mechanism of stunned myocardium. Circulation. 1996;94:2597–2604.[Abstract/Free Full Text]

59. Rowe GT, Manson NH, Caplan M, Hess ML. Hydrogen peroxide and hydroxyl radical mediation of activated leukocyte depression of cardiac sarcoplasmic reticulum: participation of the cyclooxygenase pathway. Circ Res. 1983;53:584–591.[Abstract/Free Full Text]

60. Carrozza JP, Bentivegna LA, Williams CP, Kuntz RE, Grossman W, Morgan JP. Decreased myofilament responsiveness in myocardial stunning follows transient calcium overload during ischemia and reperfusion. Circ Res. 1992;71:1334–1340.[Abstract/Free Full Text]

61. Gao WD, Atar D, Backx PH, Marban E. Relationship between intracellular calcium and contractile force in stunned myocardium: direct evidence for decreased myofilament Ca²⁺ sensitivity and altered diastolic function in intact ventricular muscle. Circ Res. 1995;76:1036–1048.[Abstract/Free Full Text]

62. Krause SM, Jacobus WE, Becker LC. Alterations in cardiac sarcoplasmic reticulum calcium transport in the postischemic `stunned' myocardium. Circ Res. 1989;65:526–530.[Abstract/Free Full Text]

63. Kitakaze M, Weisfeldt ML, Marban E. Acidosis during early reperfusion prevents myocardial stunning in perfused ferret hearts. J Clin Invest. 1988;82:920–927.

64. Hofmann PA, Miller WP, Moss RL. Altered calcium sensitivity of isometric tension in myocyte-sized preparations of porcine postischemic stunned myocardium. Circ Res. 1993;72:50–56.[Abstract/Free Full Text]

65. Miller WP, McDonald KS, Moss RL. Onset of reduced Ca²⁺ sensitivity of tension during stunning in porcine myocardium. J Moll Cell Cardiol. 1996;28:689–697.

66. Gao WD, Atar D, Liu Y, Perez NO, Murphy AM, Marban E. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res. 1997;80:393–399.

67. McDonald KS, Mammen PPA, Strang KT, Moss RL, Miller WP. Isometric and dynamic contractile properties of porcine skinned cardiac myocytes after stunning. Circ Res. 1995;77:964–972.[Abstract/Free Full Text]

68. Ellis SG, Wynne J, Braunwald E, Henschke CI, Sandor T, Kloner RA. Response of reperfusion-salvaged, stunned myocardium to inotropic stimulation. Am Heart J. 1984;107:13–19.[Medline] [Order article via Infotrieve]

69. Arnold JMO, Braunwald E, Sandor T, Kloner RA. Inotropic stimulation of reperfused myocardium: effects on infarct size and myocardial function. J Am Coll Cardiol. 1988;6:1026–1034.

70. Becker LC, Levine JH, DiPaula AF, Guarnieri T, Aversano T. Reversal of dysfunction in postischemic stunned myocardium by epinephrine and postextrasystolic potentiation. J Am Coll Cardiol. 1986;7:580–589.[Abstract]

71. Gao WD, Liu Y, Marban E. Mechanism of decreased myofilament Ca²⁺ responsiveness in stunned rat ventricular myocardium: relative roles of cytosolic factors versus structural alterations. Circ Res. 1996;78:455–465.[Abstract/Free Full Text]

72. Sun J-Z, Tang X-L, Knowlton AA, Park S-W, Qiu Y, Bolli R. Late preconditioning against myocardial stunning: an endogenous protective mechanism that confers resistance to postischemic dysfunction 24 hours after brief ischemia in conscious pigs. J Clin Invest. 1995;95:388–403.

73. Shen Y-T, Vatner SF. Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pigs: hibernation versus stunning? Circ Res. 1995;73:479–488.

74. Bolli R. Myocardial `stunning' in man. Circulation. 1992;86:1671–1691.[Free Full Text]

75. Ataka K, Chen D, Levitsky S, Jimenez E, Feinberg H. Effect of aging on intracellular Ca,²⁺ pH_i, and contractility during ischemia and reperfusion. Circulation. 1992;86(suppl II):II-371–II-376.

76. McCully JD, Tsukube T, Ataka K, Krukenkamp IB, Feinberg H, Levitsky S. Myocardial cytosolic calcium accumulation during ischemia/reperfusion: the effects of aging and cardioplegia. J Cardiothorac Surg. 1994;9:449–452.

77. Tsukube T, McCully JD, Faulk EA, Federman M, LoCicero J III, Krukenkamp IB, Levitsky S. Magnesium cardioplegia reduces cytosolic and nuclear calcium and DNA fragmentation in the senescent myocardium. Ann Thorac Surg. 1994;58:1005–1011.[Abstract]

78. Patel B, Kloner RA, Przyklenk K, Braunwald E. Postischemic myocardial `stunning': a clinically relevant phenomenon. Ann Intern Med. 1988;108:626–629.

79. Kloner RA, Przyklenk K, Patel B. Altered myocardial states: the stunned and hibernating myocardium. Am J Med. 1989;86(suppl 1A):14–22.

80. Kloner RA, Przyklenk K, Rahimtoola S, Braunwald E. Myocardial stunning and hibernation: mechanisms and clinical implications. In: Braunwald E, ed. Heart Disease: Update II. Philadelphia, Pa: WB Saunders; 1990:241–256.

81. Touchstone DA, Beller GA, Nygaard TW, Tedesco C, Karl S. Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a tomographic assessment using two-dimension echocardiography. J Am Coll Cardiol. 1989;13:1506–1513.[Abstract]

82. Stack RS, Phillips HR, Grierson D, Behar VS, Kong Y, Peter RH, Swain JL, Greenfield JC. Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. J Clin Invest. 1983;72:84–95.

83. Sheehan FH, Doerr R, Schmidt WG, Bolson EI, Uebis R, Von Essen R, Effert S, Dodge HT. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol. 1988;12:289–300.[Abstract]

84. Reduto LA, Freund GC, Gaeta JM, Smalling RW, Lewis B, Gould KL. Coronary artery reperfusion in acute myocardial infarction: beneficial effects of intracoronary streptokinase on left ventricular salvage and performance. Am Heart J. 1981;102:1168–1177.[Medline] [Order article via Infotrieve]

85. Satler LF, Kent KM, Fox LM, Goldstein HA, Green CE, Rogers WJ, Pallas RS, Del Negro AA, Pearle DL, Rackley CF. The assessment of contractile reserve after thrombolytic therapy for acute myocardial infarction. Am Heart J. 1986;111:821–825.[Medline] [Order article via Infotrieve]

86. Kloner RA, Przyklenk K, Kay GL. Clinical evidence for stunned myocardium after coronary artery bypass surgery. J Cardiac Surg. 1994;9(suppl):397–402.

87. Gray R, Maddhai J, Berman D, Raymond M, Waxman A, Ganz W, Matloff J, Swan HJC. Scintigraphic and hemodynamic demonstration of transient left ventricular dysfunction immediately after uncomplicated coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1979;77:504–510.[Medline] [Order article via Infotrieve]

88. Breisblatt WM, Stein KL, Wolfe CJ, Follansbee WP, Capozzi J, Armitage JM, Hardesty RL. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. J Am Coll Cardiol. 1990;15:1261–1269.[Abstract]

89. Bolli R, Hartley CJ, Rabinovitz RS. Clinical relevance of myocardial `stunning' In: Opie LH, ed. Stunning, Hibernation and Calcium in Myocardial Ischemia and Reperfusion. Boston, Mass: Kluwer Academic Publishers; 1992:56–82.

90. Kloner RA, Allen J, Cox TA, Zheng Y, Ruiz CE. Stunned left ventricular myocardium following exercise treadmill testing in coronary artery disease. Am J Cardiol. 1991;68:329–334.[Medline] [Order article via Infotrieve]

91. Ambrosio G, Betocchi S, Pace L, Losi MA, Perrone-Filardi P, Soricelli A, Piscione F, Taube J, Squame F, Salvatore M, Weiss JL, Chiariello M. Prolonged impairment of regional contractile function after resolution of exercise-induced angina: evidence of myocardial stunning in patients with coronary artery disease. Circulation. 1996;94:2455–2464.[Abstract/Free Full Text]

92. Fragasso G, Benti R, Sciammarella M, Rossetti E, Savi A, Gerundini P, Chierchia SL. Symptom-limited exercise testing causes sustained diastolic dysfunction in patients with coronary artery disease and low effort tolerance. J Am Coll Cardiol. 1991;17:1251–1255.[Abstract]

93. Wijns W, Serruys PW, Slager CJ, Grimm J, Kragenbuehl HP, Hugenholtz PG, Hess OM. Effect of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional diastolic pressure radius relations. J Am Coll Cardiol. 1986;7:455–461.[Abstract]

94. Sheiban I, Tonni S, Marini A, Trevi G. Clinical and therapeutic implications of chronic left ventricular dysfunction in coronary artery disease. Am J Cardiol. 1995;75:22E–30E.

95. Nixon JV, Brown CN, Smitherman TC. Identification of transient and persistent segmental wall motion abnormalities in patients with unstable angina by two-dimensional echocardiography. Circulation. 1982;65:1497–1503.[Abstract/Free Full Text]

96. Dorheim TA, Hoffman A, Van Wylen DGL, Mentzer RM. Enhanced interstitial fluid adenosine attenuates myocardial stunning. Surgery. 1991;110:136–145.[Medline] [Order article via Infotrieve]

97. Sekili S, Jeroudi MO, Tang X-L, Zughaib M, Sun JZ, Bolli R. Effect of adenosine on myocardial `stunning' in the dog. Circ Res. 1995;76:82–94.[Abstract/Free Full Text]

98. Zughaib ME, Abd-Elfattah AS, Jeroudi MO, Sun JZ, Sekili S, Tang X-L, Bolli R. Augmentation of endogenous adenosine attenuates myocardial `stunning' independently of coronary flow or hemodynamic effects. Circulation. 1993;88:2359–2369.[Abstract/Free Full Text]

99. Auchampach JA, Maruyama M, Cavero I, Gross GJ. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation. 1992;86:311–319.[Abstract/Free Full Text]

100. Przyklenk K, Kloner RA. Calcium antagonists as treatment for the stunned myocardium. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations. New York, NY: Marcel Dekker Inc; 1993:281–301.

101. Heusch G. Myocardial stunning: a role for calcium antagonists during ischaemia? Cardiovasc Res. 1992;26:14–19.[Medline] [Order article via Infotrieve]

102. Park SW, Tang XL, Qiu Y, Sun JZ, Bolli R. Nisoldipine attenuates myocardial stunning induced by multiple coronary occlusions in conscious pigs and this effect is independent of changes in hemodynamics or coronary blood flow. J Mol Cell Cardiol. 1996;28:655–666.[Medline] [Order article via Infotrieve]

103. Zughaib ME, Sun JZ, Bolli R. Effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury: an overview. In: Grobecker H, Heusch G, Strauer BE, eds. Angiotensin and the Heart. New York, NY: Springer-Verlag; 1993:156–157.

104. Ehring T, Baumgart D, Krajcar M, Hummelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation. 1994;90:1368–1385.[Abstract/Free Full Text]

105. Rahimtoola S. Coronary bypass surgery for chronic angina–1981: a perspective. Circulation. 1982;65:225–241.[Free Full Text]

106. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1985;72(suppl V):V-123–V-135.

107. Rees G, Bristow JD, Kremkau EL, Green GS, Herr RH, Griswold HE, Starr A. Influence of aortocoronary bypass surgery on left ventricular performance. N Engl J Med. 1971;284:1116–1120.

108. Chatterjee K, Swan HJC, Parmley WW, Sustaita H, Marcus HS, Matloff J. Influence of direct myocardial revascularization on left ventricular asynergy and function in patients with coronary disease. Circulation. 1973;47:276–286.[Abstract/Free Full Text]

109. Horn HR, Teichholz LE, Cohn PF, Herman MV, Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine: the epinephrine ventriculogram. Circulation. 1974;49:1063–1071.[Abstract/Free Full Text]

110. Dyke SH, Cohn PF, Gorlin R, Sonnenblick EH. Detection of residual myocardial function in coronary artery disease using post-extra systolic potentiation. Circulation. 1974;50:694–699.[Abstract/Free Full Text]

111. Rozanski A, Berman D, Gray R, Diamond G, Raymond M, Prause J, Maddahi J, Swan HJC, Matloff J. Preoperative prediction of reversible myocardial asynergy by postexercise radionuclide ventriculography. N Engl J Med. 1982;307:212–216.[Abstract]

112. Diamond GA, Forrester JS, deLuz PL, Wyatt HL, Swan HJC. Post-extrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J. 1978;95:204–209.[Medline] [Order article via Infotrieve]

113. Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117:211–221.[Medline] [Order article via Infotrieve]

114. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the hibernating myocardium. J Am Coll Cardiol. 1986;8:1467–1470. Editorial.[Medline] [Order article via Infotrieve]

115. Marban E. Myocardial stunning and hibernation: the physiology behind the colloquialisms. Circulation. 1991;83:681–688.[Free Full Text]

116. Chatterjee K, Swan HJC, Parmley WW, Sustaita H, Marcus H, Matloff J. Depression of left ventricular function due to acute myocardial ischemia and its reversal after aortocoronary saphenous vein bypass. N Engl J Med. 1972;286:1117–1122.

117. Nienaber CA, Brunken RC, Sherman CT, Yeatman LA, Gambhir SS, Krivokapich J, Demer LL, Ratib O, Child JS, Phelps ME, Schelbert HR. Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty. J Am Coll Cardiol. 1991;18:966–978.[Abstract]

118. Brundage BH, Massie BM, Botvinick EH. Improved regional ventricular function after successful surgical revascularization. J Am Coll Cardiol. 1984;3:902–908.[Abstract]

119. Rankin JS, Newman GE, Muhlbaier LH, Behar VS, Fedor JM, Sabiston DC Jr. The effect of coronary revascularization on ventricular function in ischemic heart disease. J Thorac Cardiovasc Surg. 1985;90:818–832.[Abstract]

120. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall motion abnormalities predicted by positron emission tomography. N Engl J Med. 1986;314:884–888.[Abstract]

121. Cohen M, Charney R, Hershman R, Fuster V, Gorlin R, Xavier F. Reversal of chronic ischemic myocardial dysfunction after transluminal coronary angioplasty. J Am Coll Cardiol. 1988;12:1193–1198.[Abstract]

122. Topol EJ, Weiss JL, Guzman PA, Dorsey-Lima S, Blanck TJJ, Humphrey LS, Baumgartner WA, Flaherty JT, Reitz BA. Immediate improvement of dysfunctional myocardial segments after coronary revascularization: detection by intraoperative transesophageal echocardiography. J Am Coll Cardiol. 1984;4:1123–1134.[Abstract]

123. Baker WB, Klein MS, Reardon MJ, Verani MS, Zoghbi WA. Reversible cardiac dysfunction (hibernation) from ischemia due to compression of the coronary arteries by a pseudoaneurysm. N Engl J Med. 1991;325:1858–1861.[Medline] [Order article via Infotrieve]

124. Rahimtoola SH. Myocardial hibernation: current clinical perspectives. In: Yellon DM, Rahimtoola SH, Opie LH, eds. New Ischemic Syndromes. Philadelphia, Pa: Lippincott-Raven Publishers;. 1997:215–234.

125. Breisblatt WM, Brown DL, Weiland FL. Reversibility of long-standing left ventricular aneurysm predicted by thallium-201 imaging. J Am Coll Cardiol. 1986;7:1162–1166.[Abstract]

126. Akins CW, Pohost GM, DeSanctis RW, Block PC. Selection of angina-free patients with severe left ventricular dysfunction for myocardial revascularization. Am J Cardiol. 1980;46:695–700.[Medline] [Order article via Infotrieve]

127. Nesto RW, Cohn LH, Collins JJ Jr, Wynne J, Homan L, Cohn PF. Inotropic contractile reserve: a useful predictor of increased 5 year survival and improved postoperative left ventricular function in patients with coronary artery disease and reduced ejection fraction. Am J Cardiol. 1982;50:39–44.[Medline] [Order article via Infotrieve]

128. Helfant RH, Pine R, Meister SG, Feldman MS, Trout RG, Banka VS. Nitroglycerin to unmask reversible asynergy: correlation with post coronary bypass ventriculography. Circulation. 1974;50:108–113.[Abstract/Free Full Text]

129. Kloner RA, Przyklenk K. Hibernation and stunning of the myocardium. N Engl J Med. 1991;325:1877–1879.[Medline] [Order article via Infotrieve]

130. Ragosta M, Beller GA, Watson DD, Kaul S, Gimple LW. Quantitative planar rest-redistribution ²⁰¹T1 imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation. 1993;87:1630–1641.[Abstract/Free Full Text]

131. Shivalkar B, Maes A, Borgers M, Ausma J, Scheys I, Nuyts J, Mortelmans L, Flameng W. Only hibernating myocardium invariably shows early recovery after coronary revascularization. Circulation. 1996;94:308–315.[Abstract/Free Full Text]

132. Vom Dahl J, Altehoefer C, Sheehan FH, Buechin P, Uebis R, Messmer BJ, Buell U, Hanrath P. Recovery of regional left ventricular dysfunction after coronary revascularization. J Am Coll Cardiol. 1996;28:948–958.[Abstract]

133. Gerwitz H, Fischman AJ, Abraham S, Gilson M, Strauss HW, Alpert NM. Positron emission tomographic measurements of absolute regional myocardial blood flow permits identification of nonviable myocardium in patients with chronic myocardial infarction. J Am Coll Cardiol. 1994;23:851–859.[Abstract]

134. Schwarz ER, Przyklenk K, Dahl JV, Schoendube FA, Hanrath P, Kloner RA. Chronic hibernating myocardium: concepts and controversies. Congestive Heart J. 1997;3:12–23.

135. Vanoverschelde JL, Wijns W, Depre C, Essamri B, Heyndrickx GR, Borgers M, Bol A, Melin JA. Mechanisms of chronic regional postischemic dysfunction in humans: new insights from the study of noninfarcted collateral-dependent myocardium. Circulation. 1993;87:1513–1523.[Abstract/Free Full Text]

136. Marinho NVS, Keogh BE, Costa DC, Lammertsma AA, Ell PJ, Camici PG. Pathophysiology of chronic left ventricular dysfunction: new insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation. 1996;93:734–744.

137. Conversano A, Walsh JF, Geltman EM, Perez JE, Bergmann SP, Gropler RJ. Delineation of myocardial stunning and hibernation by positron emission tomography in advanced coronary artery disease. Am Heart J. 1996;131:440–450.[Medline] [Order article via Infotrieve]

138. Gerber BL, Vanoverschelde J-L, Bol A, Michel C, Labar D, Wijns W, Melin JA. Myocardial blood flow, glucose uptake and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction: implications for the pathophysiology of chronic hibernation. Circulation. 1996;94:651–659.[Abstract/Free Full Text]

139. Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE, Moerlein SM, Sobel BE, Bergmann SR, Siegel BA. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol. 1992;20:569–577.[Abstract]

140. Hendel RC, Chaudhry FA, Bonow RO. Myocardial viability. Curr Probl Cardiol. 1996;21:145–224.[Medline] [Order article via Infotrieve]

141. Schelbert HR. Metabolic imaging to assess myocardial viability. J Nucl Med. 1994;35:8S–14S.

142. Sun DT, Czernin J, Krivokapich J, Lau Y-K, Bottcher M, Maurer G, Phelps ME, Schelbert HR. Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. Circulation. 1996;94:3146–3154.[Abstract/Free Full Text]

143. Marwick TH, MacIntyre WJ, Lafont A, Nemec JJ, Salcedo EE. Metabolic responses of hibernating and infarcted myocardium to revascularization: a follow-up study of regional perfusion, function, and metabolism. Circulation. 1992;85:1347–1353.[Abstract/Free Full Text]

144. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in hibernating and stunned myocardium. Circulation. 1993;87:1–20.[Free Full Text]

145. Bonow RO. Identification of viable myocardium. Circulation. 1996;94:2674–2680.[Free Full Text]

146. Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med. 1994;35:707–715.[Abstract/Free Full Text]

147. Beller GA. Comparison of ²⁰¹Tl scintigraphy and low-dose dobutamine echocardiography for the noninvasive assessment of myocardial viability. Circulation. 1996;94:2681–2684.[Free Full Text]

148. La Canna G, Alfieri O, Giubbini R, Gargano M, Ferrari R, Visioli O. Echocardiography during infusion of dobutamine for identification of reversible dysfunction in patients with chronic coronary artery disease. J Am Coll Cardiol. 1994;23:617–626.[Abstract]

149. Sawada S, Eisner G, Segar DS, O'Shaughnessy M, Khouri S, Foltz J, Bopurdillion PD, Bates JR, Fineberg N, Ryan T, Hutchins GD. Evaluation of patterns of perfusion and metabolism in dobutamine-responsive myocardium. J Am Coll Cardiol. 1997;29:55–61.[Abstract]

150. Heusch G, Schulz R. Recruitment of an inotropic reserve in hibernating and stunned myocardium. In: Opie LH, ed. Stunning, Hibernation, and Calcium in Myocardial Ischemia and Reperfusion. Norwell, Mass: Kluwer Academic Publishers; 1992:235–250.

151. McGhie AI, Weyman A. Searching for hibernating myocardium: time to reevaluate investigative strategies? Circulation. 1996;94:2685–2686.[Free Full Text]

152. Maes A, Flameng W, Nuyts J, Borgers M, Shivalkar B, Ausma J, Bormans G, Schiepers C, De Roo M, Mortelmans L. Histological alterations in chronically hypoperfused myocardium: correlation with PET findings. Circulation. 1994;90:735–745.[Abstract/Free Full Text]

153. Borgers M, Thone F, Wouters L, Ausma J, Shivalkar B, Flameng W. Structural correlates of regional myocardial dysfunction in patients with critical coronary stenosis: chronic hibernation? Cardiovasc Pathol. 1993;2:237–245.

154. Schwarz ER, Schaper J, vom Dahl J, Altehoefer C, Grohmann B, Schoendube F, Sheehan FH, Uebis R, Buell U, Messmer BJ, Schaper W, Hanrath P. Myocyte degeneration and cell death in hibernating human myocardium. J Am Coll Cardiol. 1996;7:1577–1585.

155. Rahimtoola SH. Hibernating myocardium has reduced blood flow at rest that increases with low-dose dobutamine. Circulation. 1996;94:3055–3061.[Free Full Text]

156. Schulz R, Guth BD, Pieper K, Martin C, Heusch G. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery: a model of short-term hibernation. Circ Res. 1992;70:1282–1295.[Abstract/Free Full Text]

157. Arai AE, Pantely GA, Thoma WJ, Anselone CG, Bristow JD. Energy metabolism and contractile function after 15 beats of moderate myocardial ischemia. Circ Res. 1992;70:1137–1145.[Abstract/Free Full Text]

158. Matsuzaki M, Gallagher KP, Kemper WS, White F, Ross J Jr. Sustained regional dysfunction produced by prolonged coronary stenosis: gradual recovery after reperfusion. Circulation. 1983;68:170–182.[Abstract/Free Full Text]

159. Pantely GA, Malone SA, Rhen WS, Anselone CG, Arai A, Bristow J, Bristow JD. Regeneration of myocardial phosphocreatinine in pigs despite continued moderate ischemia. Circ Res. 1990;67:1481–1493.[Abstract/Free Full Text]

160. Fedele FA, Gerwirtz H, Capone RJ, Sharaf B, Most AS. Metabolic response to prolonged reduction of myocardial blood flow distal to a severe coronary artery stenosis. Circulation. 1988;78:729–735.[Abstract/Free Full Text]

161. Canty JM, Fallavollita JA. Hibernating myocardium represents a primary downregulation of regional myocardial oxygen consumption distal to a critical stenosis. Basic Res Cardiol. 1995;90:5–8.[Medline] [Order article via Infotrieve]

162. Canty JM, Klocke FS. Reduction in regional myocardial function at rest in conscious dogs with chronically reduced regional coronary artery pressure. Circ Res. 1987;61(suppl II):107–116.

163. Mills I, Fallon JT, Wrenn D, Sasken H, Gray W, Brier S, Levine D, Berman S, Gilson M, Gerwtiz H. Adaptive responses of coronary circulation and myocardium to chronic reduction in perfusion pressure and flow. Am J Physiol. 1994;266(Heart Circ Physiol 35):H447–H457.

164. Ross J Jr. Myocardial hibernation, stunning, or both? In: Heusch G, Schulz R, eds. New Paradigms of Coronary Artery Disease: Hibernation, Stunning, Ischemic Preconditioning. New York, NY: Springer; 1996:42–44.

165. Heyndrickx GR. Hibernating myocardium. In: Heusch G, Schulz R, eds. New Paradigms of Coronary Artery Disease: Hibernation, Stunning, Ischemic Preconditioning. New York, NY: Springer; 1996:36–38.

166. Shen YT, Kudej RK, Bishop SP, Vatner SF. Inotropic reserve and histological appearance of hibernating myocardium in conscious pigs with ameroid-induced coronary stenosis. Basic Res Cardiol. 1996;91:479–485.[Medline] [Order article via Infotrieve]

167. Bonow RO. The hibernating myocardium: implications for the management of congestive heart failure. Am J Cardiol. 1995;75:17A–25A.[Medline] [Order article via Infotrieve]

168. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;75:1124–1136.[Abstract/Free Full Text]

169. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol. 1994;24:1133–1142.[Abstract]

170. Nao BS, McClanahan TB, Groh MA, Schott RJ, Gallagher KP. The time limit of effective ischemic preconditioning in dogs. Circulation. 1990;82(suppl III):III-271. Abstract.

171. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation. 1993;88:1264–1272.[Abstract/Free Full Text]

172. Kazuya T, Hashida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. 1993;72:1293–1299.[Abstract/Free Full Text]

173. Yamashita N, Kuzuya T, Hoshida S, Nishida M, Igarashi J, Hori K, Kamada T, Tada M. A `second window of protection' occurs 24 hours after ischemic preconditioning in rat heart. J Mol Cell Cardiol. 1995;27:A517. Abstract.

174. Kaeffer N, Richard V, Thuillez C. Delayed beneficial effects of preconditioning against reperfusion-induced coronary endothelial dysfunction. Eur Heart J. 1996;17:P1501. Abstract.

175. Murry CD, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res. 1990;66:913–931.[Abstract/Free Full Text]

176. Hagar JM, Hale SL, Kloner RA. Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res. 1991;68:61–68.[Abstract/Free Full Text]

177. Shihi K, Hearse DJ. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol. 1987;253:H1470–H1476.[Abstract/Free Full Text]

178. Asimakis GK, Inners-McBride K, Medellen G, Conti VR. Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart. Am J Physiol. 1992;263:H887–H894.[Abstract/Free Full Text]

179. Ovize M, Przyklenk K, Kloner RA. Preconditioning does not attenuate myocardial stunning. Circulation. 1992;85:2247–2254.[Abstract/Free Full Text]

180. Connaughton M, Hearse DJ. Three questions about preconditioning. Basic Res Cardiol. 1996;91:12–15.[Medline] [Order article via Infotrieve]

181. Przyklenk K, Kloner RA. Preconditioning: a balanced perspective. Br Heart J. 1995;74:575–577.[Free Full Text]

182. Jennings RB. Overview of preconditioning against lethal cell injury. In: Marber MS, Yellon DM, eds. Ischemia: Preconditioning and Adaptation. Oxford, UK: Bios Scientific Publisher; 1996.

183. Cohen MV, Downey JM. Ischaemic preconditioning: can the protection be bottled? Lancet. 1993;324:6.

184. Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson DA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A₁ adenosine receptors in rabbit heart. Circulation. 1991;84:350–356.[Abstract/Free Full Text]

185. Ytrehus Y, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994;226:H1145–H1152.

186. Cohen MV, Liu Y, Liu GS, Wang P, Weinbrenner C, Condis GA, Das DK, Downey JM. Phospholipase plays a role in ischemic preconditioning in the rabbit heart. Circulation. 1996;94:1713–1718.[Abstract/Free Full Text]

187. Goto M, Liu Y, Yang X-M, Ardelle JL, Cohen MV, Downey JM. The role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995;77:611–621.[Abstract/Free Full Text]

188. Cohen MV, Liu Y, Liu G, Wang P, Weinbrenner C, Cordis GA, Das DK, Downey JM. Phospholipase D plays a role in ischemic preconditioning in rabbit heart. Circulation. 1996;94:1713–1718.

189. Hale SL, Bellows SD, Hammerman H, Kloner RA. An adenosine A₁ receptor agonist, R(-)-N-(2-phenylisopropyl)-adenosine (PIA), but not adenosine itself, acts as a therapeutic preconditioning-mimetic agent in rabbits. Cardiovasc Res. 1993;27:2140–2145.[Abstract/Free Full Text]

190. Li Y, Kloner RA. Does protein kinase C play a role in ischemic preconditioning in rat hearts? Am J Physiol. 1995;268:H426–H431.[Abstract/Free Full Text]

191. Baines CP, Goto M, Downey JM. Oxygen radical release during ischemic preconditioning triggers protection in rabbit myocardium via activation of protein kinase C. Circulation. 1996;94(suppl I):I-424. Abstract.

192. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol. 1997;29:207–216.[Medline] [Order article via Infotrieve]

193. Tritto I, D'Andrea D, Eramo N, Scognamiglio A, Simone CD, Violante A, Esposito A, Chiarello M, Ambrosio G. Oxygen radicals can induce preconditioning in rabbit hearts. Circ Res. 1997;80:743–748.[Abstract/Free Full Text]

194. Baines CP, Cohen MV, Downey JM. Protein tryosine kinase inhibitor, genistein, blocks preconditioning in isolated rabbit hearts. Circulation. 1996;94(suppl I):I-661. Abstract.

195. Armstrong SC, Downey JM, Ganote CE. Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor. Cardiovasc Res. 1994;28:72–77.[Abstract/Free Full Text]

196. Armstrong SC, Ganote CE. Preconditioning of isolated rabbit cardiomyocytes: effects of glycolytic blockade, phorbol esters, and ischemia. Cardiovasc Res. 1994;28:1700–1706.[Abstract/Free Full Text]

197. Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5'nucleotidase activity during myocardial ischemia and reperfusion in dogs: implications for myocardial salvage. Circulation. 1993;87:208–215.[Abstract/Free Full Text]

198. Przyklenk K, Hata K, Kloner RA. Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? Circulation. 1997;96:1305–1312.[Abstract/Free Full Text]

199. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Cardioprotection with ischemic preconditioning and MLA: role of adenosine-regulating enzymes? Am J Physiol. 1997;271:H1004–H1014.

200. Przyklenk K, Hata K, Zhao L, Kloner RA, Elliott GT. Disparate effects of preconditioning and MLA on 5'NT and adenosine levels during coronary occlusion. Am J Physiol. 1997;273:H945–H951.[Abstract/Free Full Text]

201. Ovize M, Loufoua J, Gysembergh A, Andre-Foucet X, Mincore Y. Role of tyrosine phosphorylation in ischemic preconditioning. Circulation. 1996;94(suppl I):I-661. Abstract.

202. Shipolini AR, Aalinones M, Edmondson SJ, Hearse SJ, Avkiran M. Activation of the Na/H exchanger is not causally involved in ischemic preconditioning. Circulation. 1996;94(suppl I):I-424. Abstract.

203. Przyklenk K, Sussman MA, Simkhovich BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation. 1995;92:1546–1557.[Abstract/Free Full Text]

204. Vogt AM, Htun P, Arras M, Podzaweit T, Schaper W. Intramyocardial infusion of tool drugs for the study of molecular mechanisms in ischemic preconditioning. Basic Res Cardiol. 1996;91:389–400.[Medline] [Order article via Infotrieve]

205. Valhaus C, Schulz R, Post H, Onallch R, Heusch A. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res. 1996;79:407–414.[Abstract/Free Full Text]

206. Ping P, Zhang J, Qiu Y, Tang XL, Manchikalapudi S, Cao X, Bolli R. Ischemic preconditioning induces selective translocation of PKC isoforms and in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res.. 1997;81:404–414.[Abstract/Free Full Text]

207. Goldberg M, Zhang HL, Steinberg SF. Hypoxia alters the subcellular distribution of protein kinase C isoforms on neonatal rat ventricular myocytes. J Clin Invest. 1996;99:55–61.[Medline] [Order article via Infotrieve]

208. Mitchell MB, Meng X, Ao L, Brown JM, Harker AH, Banerjee A. Preconditioning of isolated rat heart mediated by protein kinase C. Circ Res. 1995;76:73–81.[Abstract/Free Full Text]

209. Brooks A, Hearse DJ. Role of protein kinase C in ischemic preconditioning: player or spectator? Circ Res. 1996;79:627–630.

210. Armstrong SC, Gao W, Lane JR, Ganote CE. Protein phosphatase inhibitors Calyculin A and Fostriecin protect rabbit cardiomyocytes in late ischemia. J Mol Cell Cardiol. 1998;30:61–74.[Medline] [Order article via Infotrieve]

211. Gross GJ, Auchampach JA. Blockade of ATP sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992;70:223–233.[Abstract/Free Full Text]

212. Auchampach JA, Grover GJ, Gross GJ. Blockade of ischemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist 5-hydroxydecanoate. Cardiovasc Res. 1992;26:1054–1062.[Abstract/Free Full Text]

213. Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol. 1993;264:H2221–H2235.[Abstract/Free Full Text]

214. Yao Z, Gross GJ. A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs: efficacy, time course, and role of K_ATP channels. Circulation. 1994;89:1229–1236.[Abstract/Free Full Text]

215. Fralix TA, Steenbergen C, London RE, Murphy E. Glibenclamide does not abolish the protective effect of preconditioning on stunning in the isolated perfused rat heart. Cardiovasc Res. 1993;27:630–637.[Medline] [Order article via Infotrieve]

216. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat heart. Am J Physiol. 1992;263:H1107–H1112.[Abstract/Free Full Text]

217. Thornton JD, Thornton DL, Sterling DL, Downey JM. Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts. Circ Res. 1993;72:44–49.[Abstract/Free Full Text]

218. Schultz JEJ, Yao Z, Cavero I, Gross GJ. Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am J Physiol. 1997;272:H2607–H2615.[Abstract/Free Full Text]

219. Yellon DM, Baxter GF. `A second window of protection' or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol. 1995;27:1023–1024.[Medline] [Order article via Infotrieve]

220. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation. 1993;88:1264–1272.

221. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res. 1994;75:586–590.[Abstract/Free Full Text]

222. Baxter GF, Goma FM, Yellon DM. Characterization of the infarct-limiting effect of delayed preconditioning: time course and dose dependency studies in rabbit myocardium. Basic Res Cardiol. 1997;92:159–167.[Medline] [Order article via Infotrieve]

223. Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of protection 24 hours following ischemic preconditioning. Circulation. 1994;90:2993–3006.[Abstract/Free Full Text]

224. Baxter GF, Goma FM, Yellon DM. Involvement of protein kinase C in the delayed cytoprotection following sublethal ischaemia in rabbit myocardium. Br J Pharmacol. 1995;115:222–224.[Medline] [Order article via Infotrieve]

225. Marber MS, Mestril R, Chi SH, Sager R, Yellon DM, Dillmann WH. Overexpression of the rat inducible 70-kd heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest. 1995;95:1446–1456.

226. Sun JZ, Tang XL, Knowlton AA, Park SW, Qui YM, Bolli R. Late preconditioning against myocardial stunning: an endogenous protective mechanism that confers resistance to postischemic dysfunction 24 hours after brief ischemia in conscious pigs. J Clin Invest. 1995;95:388–403.

227. Sun JZ, Tang XL, Park SW, Qiu Y, Turrens JF, Bolli R. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest. 1996;97:562–576.

228. Bolli R, Bhatti ZA, Tang X-L, Qiu Y, Zhang Q, Guo Y, Yadoon AK. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ Res. 1997;81:42–52.[Abstract/Free Full Text]

229. Qiu Y, Rizvi A, Tang X-L, Manchikalapudi S, Takano H, Jadoon AK, Wu W-J, Bolli R. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol. 1997;273:H2931–H2936.

230. Qiu Y, Tang X-L, Park S-W, Sun J-Z, Kalya A, Bolli R. The early and late phase of ischemic preconditioning: a comparative analysis of their effect on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-minute coronary occlusion. Circ Res. 1997;80:730–742.[Abstract/Free Full Text]

231. Zimmer SD, Bache RJ. Metabolic correlates of reversibly injured myocardium. In: Kloner RA, Przyklenk K, eds. Stunned Myocardium: Properties, Mechanisms and Clinical Manifestations. New York, NY: Marcel Dekker Inc; 1993:41–70.

232. Murry CE, Richard VJ, Jennings RB, Reimer KA. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am J Physiol. 1991;260:H796–H804.[Abstract/Free Full Text]

233. Matsuda M, Catena TG, Vander Heide RS, Jennings RB, Reimer KA. Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning. Cardiovasc Res. 1993;27:585–592.[Medline] [Order article via Infotrieve]

234. Ikonomidis JS, Weisel RD, Mickle DAG. Ischemic preconditioning: cardioprotection for cardiac surgery. J Card Surg. 1994;9(suppl):526–531.

235. Yellon DM, Alkulaif AM, Pugsley WB. Preconditioning the human myocardium. Lancet. 1993;342:276–277.[Medline] [Order article via Infotrieve]

236. Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper J, Yellon DM. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart. 1997;77:314–318.[Abstract/Free Full Text]

237. Walker DM, Walker JM, Pugsley WB, Pattison CW, Yellon DM. Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol. 1995;27:1349–1357.[Medline] [Order article via Infotrieve]

238. Speechly-Dick ME, Grover GJ, Yellon DM. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Circ Res. 1995;77:1030–1035.[Abstract/Free Full Text]

239. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrman HC, Lashey WL. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation. 1990;82:2044–2051.[Abstract/Free Full Text]

240. Cribier A, Korsatz L, Koning R, Rath P, Gamra H, Stix G, Merchant S, Chan C, Letac B. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol. 1992;20:578–586.[Abstract]

241. Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation. 1997;95:2500–2507.[Abstract/Free Full Text]

242. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Polisca P, Chiariello L, Gioffre PA. Effects of A₁ adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty. Eur Heart J. 1996;17:846–853.[Abstract/Free Full Text]

243. Claeys MJ, Vrints CJ, Bosmans JM, Concraads VM, Snoeck JP. Aminophylline inhibits adaptation to ischemia during angioplasty: role of adenosine in ischaemic preconditioning. Eur Heart J. 1996;17:539–544.[Abstract/Free Full Text]

244. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, McCabe C, Braunwald E, for TIMI Investigators. Previous angina alters in-hospital outcome in TIMI 4: a clinical correlate to preconditioning? Circulation. 1995;91:37–47.[Abstract/Free Full Text]

245. Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, Rusticali F. Prodromal angina limits infarct size: a role for ischemic preconditioning. Circulation. 1995;21:291–297.

246. Anzai T, Yoshikawa T, Asakura Y, Abe S, Meguno T, Akaishi M, Mitamura H, Handa S, Ogawa S. Effect on short-term prognosis and left ventricular function of angina pectoris prior to first Q-wave anterior wall acute myocardial infarction. Am J Cardiol. 1994;74:755–759.[Medline] [Order article via Infotrieve]

247. Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, McCabe CH, Braunwald E, TIMI 9 Investigators. A prospective analysis on the potential preconditioning effect of preinfarct angina in TIMI 9. Circulation. 1996;94(suppl I):I-611. Abstract.

248. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K, Ueda K. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol. 1997;30:970–975.[Abstract]

249. Andreotti F, Pasceri V, Hackett DR, Davies GJ, Harder AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med. 1996;334:7–12.[Abstract/Free Full Text]

250. Okazaki Y, Kodama K, Sato H, Mafasumi K, Atsushi H, Masayoshi M, Masatsugu H, Michitoshi I. Attenuation of increased regional myocardial oxygen consumption during exercise as a major cause of warm-up phenomenon. J Am Coll Cardiol. 1993;21:1597–1604.[Abstract]

251. Maybaum S, Ilan M, Mogilevsky J, Tzivoni D. Improvement in ischemic parameters during repeated exercise testing: a possible model for myocardial preconditioning. Am J Cardiol. 1996;78:1087–1091.[Medline] [Order article via Infotrieve]

252. Mentzer RM Jr, Rahko PS, Molina-Viamonte V, Canver CC, Chopra PS, Love RL, Cook TD, Hegge JO, Lasley RD. Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am J Cardiol. 1997;79(suppl 12A):38–43.

This article has been cited by other articles:

				C. S. Metcalf, S. Poelzing, J. G. Little, and S. L. Bealer Status epilepticus induces cardiac myofilament damage and increased susceptibility to arrhythmias in rats Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2120 - H2127. [Abstract] [Full Text] [PDF]

				T. Kobayashi, Y. Watanabe, Y. Saito, D. Fujioka, T. Nakamura, J.-e. Obata, Y. Kitta, T. Yano, K. Kawabata, K. Watanabe, et al. Mice lacking the glutamate-cysteine ligase modifier subunit are susceptible to myocardial ischaemia-reperfusion injury Cardiovasc Res, November 21, 2009; (2009) cvp342v2. [Abstract] [Full Text] [PDF]

				M. Carlsson, J. F.A. Ubachs, E. Hedstrom, E. Heiberg, S. Jovinge, and H. Arheden Myocardium at risk after acute infarction in humans on cardiac magnetic resonance quantitative assessment during follow-up and validation with single-photon emission computed tomography. J. Am. Coll. Cardiol. Img., May 1, 2009; 2(5): 569 - 576. [Abstract] [Full Text] [PDF]

				T. Doenst, H. Bugger, M. Schwarzer, G. Faerber, M. A. Borger, and F. W. Mohr Three good reasons for heart surgeons to understand cardiac metabolism Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 862 - 871. [Abstract] [Full Text] [PDF]

				T Bragadeesh, A R Jayaweera, M Pascotto, A Micari, D E Le, C M Kramer, F H Epstein, and S Kaul Post-ischaemic myocardial dysfunction (stunning) results from myofibrillar oedema Heart, February 1, 2008; 94(2): 166 - 171. [Abstract] [Full Text] [PDF]

				J. C. Wu, F. M. Bengel, and S. S. Gambhir Cardiovascular Molecular Imaging Radiology, August 1, 2007; 244(2): 337 - 355. [Abstract] [Full Text] [PDF]

				V. Bito, J. van der Velden, P. Claus, C. Dommke, A. Van Lommel, L. Mortelmans, E. Verbeken, B. Bijnens, G. Stienen, and K. R. Sipido Reduced Force Generating Capacity in Myocytes From Chronically Ischemic, Hibernating Myocardium Circ. Res., February 2, 2007; 100(2): 229 - 237. [Abstract] [Full Text] [PDF]

				H. Ardehali Signaling Mechanisms in Ischemic Preconditioning: Interaction of PKC{epsilon} and MitoKATP in the Inner Membrane of Mitochondria Circ. Res., October 13, 2006; 99(8): 798 - 800. [Full Text] [PDF]

				C. F. Azevedo, L. C. Amado, D. L. Kraitchman, B. L. Gerber, T. Edvardsen, N. F. Osman, C. E. Rochitte, K. C. Wu, and J. A.C. Lima The effect of intra-aortic balloon counterpulsation on left ventricular functional recovery early after acute myocardial infarction: a randomized experimental magnetic resonance imaging study Eur. Heart J., June 2, 2005; 26(12): 1235 - 1241. [Abstract] [Full Text] [PDF]

				A. F L Schinkel, J. J Bax, and D. Poldermans Clinical assessment of myocardial hibernation Heart, January 1, 2005; 91(1): 111 - 117. [Full Text] [PDF]

				S. Barrere-Lemaire, N. Combes, C. Sportouch-Dukhan, S. Richard, J. Nargeot, and C. Piot Morphine mimics the antiapoptotic effect of preconditioning via an Ins(1,4,5)P3 signaling pathway in rat ventricular myocytes Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H83 - H88. [Abstract] [Full Text] [PDF]

				C. A. Caldarone, E. W. Barner, L. Wang, M. Karimi, C. E. Mascio, J. M. Hammel, J. L. Segar, C. Du, and T. D. Scholz Apoptosis-related mitochondrial dysfunction in the early postoperative neonatal lamb heart Ann. Thorac. Surg., September 1, 2004; 78(3): 948 - 955. [Abstract] [Full Text] [PDF]

				C. F. Azevedo, L. C. Amado, D. L. Kraitchman, B. L. Gerber, N. F. Osman, C. E. Rochitte, T. Edvardsen, and J. A.C. Lima Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging Eur. Heart J., August 2, 2004; 25(16): 1419 - 1427. [Abstract] [Full Text] [PDF]

				D. A Colantonio, J. E Van Eyk, and K. Przyklenk Stunned peri-infarct canine myocardium is characterized by degradation of troponin T, not troponin I Cardiovasc Res, August 1, 2004; 63(2): 217 - 225. [Abstract] [Full Text] [PDF]

				J. Milei, C. G. Fraga, D. R. Grana, R. Ferreira, and G. Ambrosio Ultrastructural evidence of increased tolerance of hibernating myocardium to cardioplegic ischemia-reperfusion injury J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2329 - 2336. [Abstract] [Full Text] [PDF]

				V. Bito, F. R. Heinzel, F. Weidemann, C. Dommke, J. van der Velden, E. Verbeken, P. Claus, B. Bijnens, I. De Scheerder, G. J.M. Stienen, et al. Cellular Mechanisms of Contractile Dysfunction in Hibernating Myocardium Circ. Res., April 2, 2004; 94(6): 794 - 801. [Abstract] [Full Text] [PDF]

				T B Lindhardt, N Gadsboll, H Kelbaek, K Saunamaki, J K Madsen, P Clemmensen, B Hesse, and S Haunso Pharmacological modulation of the ATP sensitive potassium channels during repeated coronary occlusions: no effect on myocardial ischaemia or function Heart, April 1, 2004; 90(4): 425 - 430. [Abstract] [Full Text] [PDF]

				W. C. Stanley Myocardial Energy Metabolism During Ischemia and the Mechanisms of Metabolic Therapies Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S31 - S45. [Abstract] [PDF]

				G. A. Krombach, M. Saeed, C. B. Higgins, V. Novikov, and M. F. Wendland Contrast-enhanced MR Delineation of Stunned Myocardium with Administration of MnCl2 in Rats Radiology, January 1, 2004; 230(1): 183 - 190. [Abstract] [Full Text] [PDF]

				D. A Gorog, M. Tanno, X. Cao, M. Bellahcene, R. Bassi, A. M.N Kabir, K. Dighe, R. A Quinlan, and M. S Marber Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia Cardiovasc Res, January 1, 2004; 61(1): 123 - 131. [Abstract] [Full Text] [PDF]

				K. C. Wu and J. A.C. Lima Noninvasive Imaging of Myocardial Viability: Current Techniques and Future Developments Circ. Res., December 12, 2003; 93(12): 1146 - 1158. [Abstract] [Full Text] [PDF]

				P. Abete, F. Cacciatore, N. Ferrara, C. Calabrese, D. de Santis, G. Testa, G. Galizia, S. Del Vecchio, D. Leosco, M. Condorelli, et al. Body mass index and preinfarction angina in elderly patients with acute myocardial infarction Am. J. Clinical Nutrition, October 1, 2003; 78(4): 796 - 801. [Abstract] [Full Text] [PDF]

				D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF]

				R. Southworth and P. B. Garlick Dobutamine responsiveness, PET mismatch, and lack of necrosis in low-flow ischemia: is this hibernation in the isolated rat heart? Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H316 - H324. [Abstract] [Full Text] [PDF]

				G. M. Felker, R. L. Benza, A. B. Chandler, J. D. Leimberger, M. S. Cuffe, R. M. Califf, M. Gheorghiade, C. M. O'Connor, and OPTIME-CHF Investigators Heart failure etiology and response tomilrinone in decompensated heart failure: Results from the OPTIME-CHF study J. Am. Coll. Cardiol., March 19, 2003; 41(6): 997 - 1003. [Abstract] [Full Text] [PDF]

				O. Dewald, N. G. Frangogiannis, M. Zoerlein, G. D. Duerr, C. Klemm, P. Knuefermann, G. Taffet, L. H. Michael, J. D. Crapo, A. Welz, et al. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species PNAS, March 4, 2003; 100(5): 2700 - 2705. [Abstract] [Full Text] [PDF]

				S. Roy, S. Khanna, A. A. Bickerstaff, S. V. Subramanian, M. Atalay, M. Bierl, S. Pendyala, D. Levy, N. Sharma, M. Venojarvi, et al. Oxygen Sensing by Primary Cardiac Fibroblasts: A Key Role of p21Waf1/Cip1/Sdi1 Circ. Res., February 21, 2003; 92(3): 264 - 271. [Abstract] [Full Text] [PDF]

				D. B. Fram, R. R. Azar, A. W. Ahlberg, L. D. Gillam, J. F. Mitchel, F. J. Kiernan, J. A. Hirst, J. F. Mather, E. Ficaro, G. Cyr, et al. Duration of abnormal SPECT myocardial perfusion imaging following resolution of acute ischemia: an angioplasty model J. Am. Coll. Cardiol., February 5, 2003; 41(3): 452 - 459. [Abstract] [Full Text] [PDF]

				R J Edwards, S R Redwood, P D Lambiase, E Tomset, R D Rakhit, and M S Marber Antiarrhythmic and anti-ischaemic effects of angina in patients with and without coronary collaterals Heart, December 1, 2002; 88(6): 604 - 610. [Abstract] [Full Text] [PDF]

				E. G. Lakatta and S. J. Sollott The "Heartbreak" of Older Age Mol. Interv., November 1, 2002; 2(7): 431 - 446. [Abstract] [Full Text] [PDF]

				R. Pandey, G. Ciotti, and M. Pozzi Anomalous origin of the left coronary artery from the pulmonary artery: results of surgical correction in five infants Ann. Thorac. Surg., November 1, 2002; 74(5): 1625 - 1630. [Abstract] [Full Text] [PDF]

				H. F del Valle, E. C Lascano, and J. A Negroni Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels Cardiovasc Res, August 15, 2002; 55(3): 642 - 659. [Abstract] [Full Text] [PDF]

				A. T Saurin, D. J Pennington, N. J.H Raat, D. S Latchman, M. J Owen, and M. S Marber Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse hearts Cardiovasc Res, August 15, 2002; 55(3): 672 - 680. [Abstract] [Full Text] [PDF]

				A. C. Nicolosi, G. West, J. G. Markley, B. Logan, and G. N. Olinger Gadolinium attenuates regional stunning in the canine heart in vivo J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 57 - 62. [Abstract] [Full Text] [PDF]

				H.-Z. Zhou, J. S. Karliner, and M. O. Gray Moderate alcohol consumption induces sustained cardiac protection by activating PKC-epsilon and Akt Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H165 - H174. [Abstract] [Full Text] [PDF]

				G.D. Dispersyn, L. Mesotten, B. Meuris, A. Maes, L. Mortelmans, W. Flameng, F. Ramaekers, and M. Borgers Dissociation of cardiomyocyte apoptosis and dedifferentiation in infarct border zones Eur. Heart J., June 1, 2002; 23(11): 849 - 857. [Abstract] [Full Text] [PDF]

				S. Verma, P. W.M. Fedak, R. D. Weisel, J. Butany, V. Rao, A. Maitland, R.-K. Li, B. Dhillon, and T. M. Yau Fundamentals of Reperfusion Injury for the Clinical Cardiologist Circulation, May 21, 2002; 105(20): 2332 - 2336. [Full Text] [PDF]

				R. M. Stevens, M. S. Jahania, J. E. Stivers, R. M. Mentzer Jr, and R. D. Lasley Effects of in vivo myocardial ischemia and reperfusion on interstitial nitric oxide metabolites Ann. Thorac. Surg., April 1, 2002; 73(4): 1261 - 1266. [Abstract] [Full Text] [PDF]

				R. M. Temsah, K. Kawabata, D. Chapman, and N. S. Dhalla Preconditioning prevents alterations in cardiac SR gene expression due to ischemia-reperfusion Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1461 - H1466. [Abstract] [Full Text] [PDF]

				R. A. Kloner and R. B. Jennings Consequences of Brief Ischemia: Stunning, Preconditioning, and Their Clinical Implications: Part 2 Circulation, December 18, 2001; 104(25): 3158 - 3167. [Abstract] [Full Text] [PDF]

				R. A. Kloner and R. B. Jennings Consequences of Brief Ischemia: Stunning, Preconditioning, and Their Clinical Implications: Part 1 Circulation, December 11, 2001; 104(24): 2981 - 2989. [Abstract] [Full Text] [PDF]

				P. Abete, N. Ferrara, F. Cacciatore, E. Sagnelli, M. Manzi, V. Carnovale, C. Calabrese, D. de Santis, G. Testa, G. Longobardi, et al. High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1357 - 1365. [Abstract] [Full Text] [PDF]

				R. A. Kloner Preinfarct angina and exercise: yet another reason to stay physically active J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1366 - 1368. [Full Text] [PDF]

				P. J. Gheeraert, J. P. S. Henriques, M. L. De Buyzere, M. De Pauw, Y. Taeymans, and F. Zijlstra Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1369 - 1374. [Abstract] [Full Text] [PDF]

				D. S. Schwartz, R. M. Bremner, C. J. Baker, K. M. Uppal, M. L. Barr, R. G. Cohen, and V. A. Starnes Regional topical hypothermia of the beating heart: preservation of function and tissue Ann. Thorac. Surg., September 1, 2001; 72(3): 804 - 809. [Abstract] [Full Text] [PDF]

				B. Stadler, J. Phillips, Y. Toyoda, M. Federman, S. Levitsky, and J. D. McCully Adenosine-enhanced ischemic preconditioning modulates necrosis and apoptosis: effects of stunning and ischemia-reperfusion Ann. Thorac. Surg., August 1, 2001; 72(2): 555 - 563. [Abstract] [Full Text] [PDF]

				M. Marzilli and M. Mariani About EMIP-FR and reperfusion damage in AMI: a comment to the comment Eur. Heart J., June 1, 2001; 22(11): 973 - 975. [PDF]

				E. Braunwald Congestive heart failure: a half century perspective Eur. Heart J., May 2, 2001; 22(10): 825 - 836. [PDF]

				F. J. Giordano, H.-P. Gerber, S.-P. Williams, N. VanBruggen, S. Bunting, P. Ruiz-Lozano, Y. Gu, A. K. Nath, Y. Huang, R. Hickey, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function PNAS, April 25, 2001; (2001) 91415198. [Abstract] [Full Text]

				T. Hara, S. Tomiyasu, C. Sungsam, M. Fukusaki, and K. Sumikawa Sevoflurane Protects Stunned Myocardium Through Activation of Mitochondrial ATP-Sensitive Potassium Channels Anesth. Analg., April 1, 2001; 92(5): 1139 - 1145. [Abstract] [Full Text] [PDF]

				F. Farhat, D. Loisance, J.-P. Garnier, and M. Kirsch Norepinephrine release after acute brain death abolishes the cardioprotective effects of ischemic preconditioning in rabbit Eur. J. Cardiothorac. Surg., March 1, 2001; 19(3): 313 - 320. [Abstract] [Full Text] [PDF]

				A. C. Nicolosi, C. S. Kwok, S. J. Contney, G. N. Olinger, and Z. J. Bosnjak Gadolinium prevents stretch-mediated contractile dysfunction in isolated papillary muscles Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1122 - H1128. [Abstract] [Full Text] [PDF]

				G. D. Dispersyn and M. Borgers Apoptosis in the Heart: About Programmed Cell Death and Survival Physiology, February 1, 2001; 16(1): 41 - 47. [Abstract] [Full Text] [PDF]

				C.H. Davies Revascularization for cardiogenic shock QJM, February 1, 2001; 94(2): 57 - 67. [Full Text] [PDF]

				E. R. Gross, M. Gare, W. G. Toller, J. R. Kersten, D. C. Warltier, and P. S. Pagel Ethanol Enhances the Functional Recovery of Stunned Myocardium Independent of KATP Channels in Dogs Anesth. Analg., February 1, 2001; 92(2): 299 - 305. [Abstract] [Full Text] [PDF]

				A. T. SAURIN, J. L. MARTIN, R. J. HEADS, C. FOLEY, J. W. MOCKRIDGE, M. J. WRIGHT, Y. WANG, and M. S. MARBER The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes FASEB J, November 1, 2000; 14(14): 2237 - 2246. [Abstract] [Full Text]

				S. Jovanovic, A. Jovanovic, W. K. Shen, and A. Terzic Low concentrations of 17{beta}-estradiol protect single cardiac cells against metabolic stress-induced Ca2+ loading J. Am. Coll. Cardiol., September 1, 2000; 36(3): 948 - 952. [Abstract] [Full Text] [PDF]

				P. Theroux Myocardial Cell Protection : A Challenging Time for Action and a Challenging Time for Clinical Research Circulation, June 27, 2000; 101(25): 2874 - 2876. [Full Text] [PDF]

				B. Z. Atkins, S. C. Silvestry, R. N. Samy, A. S. Shah, D. C. Sabiston Jr, and D. D. Glower CALCITONIN GENE-RELATED PEPTIDE ENHANCES THE RECOVERY OF CONTRACTILE FUNCTION IN STUNNED MYOCARDIUM J. Thorac. Cardiovasc. Surg., June 1, 2000; 119(6): 1246 - 1254. [Abstract] [Full Text] [PDF]

				T. N. James Homage to James B. Herrick: A Contemporary Look at Myocardial Infarction and at Sickle-Cell Heart Disease : The 32nd Annual Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association Circulation, April 18, 2000; 101(15): 1874 - 1887. [Full Text] [PDF]

				G. Longobardi, P. Abete, N. Ferrara, A. Papa, R. Rosiello, G. Furgi, C. Calabrese, F. Cacciatore, and F. Rengo "Warm-Up" Phenomenon in Adult and Elderly Patients With Coronary Artery Disease: Further Evidence of the Loss of "Ischemic Preconditioning" in the Aging Heart J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2000; 55(3): 124M - 129. [Abstract] [Full Text]

				E Barnes, C S R Baker, D P Dutka, O Rimoldi, C A Rinaldi, P Nihoyannopoulos, P G Camici, and R J C Hall Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia Heart, March 1, 2000; 83(3): 283 - 289. [Abstract] [Full Text]

				C. Depre and H. Taegtmeyer Metabolic aspects of programmed cell survival and cell death in the heart Cardiovasc Res, February 1, 2000; 45(3): 538 - 548. [Abstract] [Full Text] [PDF]

				G. D. Dispersyn, M. Borgers, and W. Flameng Apoptosis in chronic hibernating myocardium: sleeping to death? Cardiovasc Res, February 1, 2000; 45(3): 696 - 703. [Abstract] [Full Text] [PDF]

				P Kay, J Kittelson, and R A H Stewart Relation between duration and intensity of first exercise and "warm up" in ischaemic heart disease Heart, January 1, 2000; 83(1): 17 - 21. [Abstract] [Full Text] [PDF]

				M. Avkiran Protection of the Myocardium During Ischemia and Reperfusion : Na+/H+ Exchange Inhibition Versus Ischemic Preconditioning Circulation, December 21, 1999; 100(25): 2469 - 2472. [Full Text] [PDF]

				S. Banerjee, X.-L. Tang, Y. Qiu, H. Takano, S. Manchikalapudi, B. Dawn, G. Shirk, and R. Bolli Nitroglycerin induces late preconditioning against myocardial stunning via a PKC-dependent pathway Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2488 - H2494. [Abstract] [Full Text] [PDF]

				M. V. Brahmajothi and D. L. Campbell Heterogeneous Basal Expression of Nitric Oxide Synthase and Superoxide Dismutase Isoforms in Mammalian Heart : Implications for Mechanisms Governing Indirect and Direct Nitric Oxide-Related Effects Circ. Res., October 1, 1999; 85(7): 575 - 587. [Abstract] [Full Text] [PDF]

				M. A. Leesar, M. F. Stoddard, S. Manchikalapudi, and R. Bolli Bradykinin-induced preconditioning in patients undergoing coronary angioplasty J. Am. Coll. Cardiol., September 1, 1999; 34(3): 639 - 650. [Abstract] [Full Text] [PDF]

				E. L Holmuhamedov, L. Wang, and A. Terzic ATP-sensitive K+ channel openers prevent Ca2+ overload in rat cardiac mitochondria J. Physiol., September 1, 1999; 519(2): 347 - 360. [Abstract] [Full Text] [PDF]

				R. D Rakhit, R. J Edwards, and M. S Marber Nitric oxide, nitrates and ischaemic preconditioning Cardiovasc Res, August 15, 1999; 43(3): 621 - 627. [Full Text] [PDF]

				E. N. Morgan, E. M. Boyle Jr, W. Yun, J. M. Griscavage-Ennis, A. L. Farr, T. G. Canty Jr, T. H. Pohlman, and E. D. Verrier An essential role for NF-{kappa}B in the cardioadaptive response to ischemia Ann. Thorac. Surg., August 1, 1999; 68(2): 377 - 382. [Abstract] [Full Text] [PDF]

				D. F. Stowe Understanding the temporal relationship of ATP loss, calcium loading, and rigor contracture during anoxia, and hypercontracture after anoxia in cardiac myocytes Cardiovasc Res, August 1, 1999; 43(2): 285 - 287. [Full Text] [PDF]

				H.-S. V. Chen, S. C. Body, and S. K. Shernan Myocardial Preconditioning: Characteristics, Mechanisms, and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 1999; 3(2): 85 - 97. [Abstract] [PDF]

				A. C. Nicolosi, J. G. Markley, and G. N. Olinger EFFECTS OF POSTISCHEMIC LEFT VENTRICULAR PRESSURE-VOLUME UNLOADINGON CONTRACTILE RECOVERY AND MYOCARDIAL BLOOD FLOW IN THE REGIONALLY STUNNEDCANINE HEART J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 181 - 188. [Abstract] [Full Text] [PDF]

				J. M. Canty Jr. and J. A. Fallavollita Resting myocardial flow in hibernating myocardium: validating animal models of human pathophysiology Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H417 - H422. [Full Text] [PDF]

				C. Perez-Terzic, A. M. Gacy, R. Bortolon, P. P. Dzeja, M. Puceat, M. Jaconi, F. G. Prendergast, and A. Terzic Structural Plasticity of the Cardiac Nuclear Pore Complex in Response to Regulators of Nuclear Import Circ. Res., June 11, 1999; 84(11): 1292 - 1301. [Abstract] [Full Text] [PDF]

				H. Hu, T. Sato, J. Seharaseyon, Y. Liu, D. C. Johns, B. O'Rourke, and E. Marbán Pharmacological and Histochemical Distinctions Between Molecularly Defined Sarcolemmal KATP Channels and Native Cardiac Mitochondrial KATP Channels Mol. Pharmacol., June 1, 1999; 55(6): 1000 - 1005. [Abstract] [Full Text]

				J. A. Fallavollita and J. M. Canty Jr Differential 18F-2-Deoxyglucose Uptake in Viable Dysfunctional Myocardium With Normal Resting Perfusion : Evidence for Chronic Stunning in Pigs Circulation, June 1, 1999; 99(21): 2798 - 2805. [Abstract] [Full Text] [PDF]

				K. W. Saupe, F. R. Eberli, J. S. Ingwall, and C. S. Apstein Hypoperfusion-induced contractile failure does not require changes in cardiac energetics Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1715 - H1723. [Abstract] [Full Text] [PDF]

				W. K. Laskey Beneficial Impact of Preconditioning During PTCA on Creatine Kinase Release Circulation, April 27, 1999; 99(16): 2085 - 2089. [Abstract] [Full Text] [PDF]

				D. Pucar, E. Janssen, P. P. Dzeja, N. Juranic, S. Macura, B. Wieringa, and A. Terzic Compromised Energetics in the Adenylate Kinase AK1 Gene Knockout Heart under Metabolic Stress J. Biol. Chem., December 22, 2000; 275(52): 41424 - 41429. [Abstract] [Full Text] [PDF]

				F. J. Giordano, H.-P. Gerber, S.-P. Williams, N. VanBruggen, S. Bunting, P. Ruiz-Lozano, Y. Gu, A. K. Nath, Y. Huang, R. Hickey, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function PNAS, May 8, 2001; 98(10): 5780 - 5785. [Abstract] [Full Text] [PDF]

				E. Barnes, D. P. Dutka, M. Khan, P. G. Camici, and R. J. Hall Effect of repeated episodes of reversible myocardial ischemia on myocardial blood flow and function in humans Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1603 - H1608. [Abstract] [Full Text] [PDF]

				P. Abete, G. Testa, N. Ferrara, D. De Santis, P. Capaccio, L. Viati, C. Calabrese, F. Cacciatore, G. Longobardi, M. Condorelli, et al. Cardioprotective effect of ischemic preconditioning is preserved in food-restricted senescent rats Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H1978 - H1987. [Abstract] [Full Text] [PDF]

				K. Imahashi, T. Nishimura, J. Yoshioka, and H. Kusuoka Role of Intracellular Na+ Kinetics in Preconditioned Rat Heart Circ. Res., June 8, 2001; 88(11): 1176 - 1182. [Abstract] [Full Text] [PDF]

				J. Muller-Ehmsen, K. L. Peterson, L. Kedes, P. Whittaker, J. S. Dow, T. I. Long, P. W. Laird, and R. A. Kloner Rebuilding a Damaged Heart: Long-Term Survival of Transplanted Neonatal Rat Cardiomyocytes After Myocardial Infarction and Effect on Cardiac Function Circulation, April 9, 2002; 105(14): 1720 - 1726. [Abstract] [Full Text] [PDF]

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kloner, R. A. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Kloner, R. A. Articles by Braunwald, E. Related Collections AHA Statements and Guidelines